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Prior work in causal modeling has focused primarily on learning graph structures 
and parameters to model data generating processes from observational or experimental 
data, while the focus of the literature-based discovery paradigm was to identify novel 
therapeutic hypotheses in publicly available knowledge. The critical contribution of this 
dissertation is to refashion the literature-based discovery paradigm as a means to populate 
causal models with relevant covariates to abet causal inference. In particular, this 
dissertation describes a generalizable framework for mapping from causal propositions in 
the literature to subgraphs populated by instantiated variables that reflect observational 
data. The observational data are those derived from electronic health records. The 
purpose of causal inference is to detect adverse drug event signals. The Principle of the 
Common Cause is exploited as a heuristic for a defeasible practical logic. The 
fundamental intuition is that improbable co-occurrences can be “explained away” with 
reference to a common cause, or confounder. Semantic constraints in literature-based 
discovery can be leveraged to identify such covariates. Further, the asymmetric semantic 
constraints of causal propositions map directly to the topology of causal graphs as 
directed edges. The hypothesis is that causal models conditioned on sets of such 
covariates will improve upon the performance of purely statistical techniques for 
detecting adverse drug event signals. By improving upon previous work in purely EHR-
based pharmacovigilance, these results establish the utility of this scalable approach to 
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Chapter 1: Introduction 
Long after the solstice, near the equinox, wintry weather returned, and at the 
actual equinoctial period there were southerly winds with snow, but not for long. 
The spring southerly again, with no winds; many rains throughout until the Dog 
Star. The summer was clear and warm, with waves of stifling heat. The Etesian 
winds were faint and intermittent. But, on the other hand, near the rising of 
Arcturus there were heavy rains with northerly winds. 
The year having proved southerly, wet and mild, in the winter the general health 
was good except for the consumptives, who will be described in due course. 
 Hippocrates, Epidemics III, pg. 241 
 
Scientific understanding progresses when evidence is marshaled to explain some hitherto 
misunderstood aspect of our world. As findings are shared, a debate within the scientific 
community ensues over their meaning and validity. The validity of any study hinges in 
part upon the integrity of the data and the suitability of the methods used to analyze them. 
Techniques that are well-suited for analyzing experimental data may not be applied 
without modification to assay observational data. In other words, novel approaches must 






This dissertation explores the accommodations necessary for using observational 
clinical data derived from electronic health records2 (EHRs) to detect putative 
drug/adverse event relationships. An adverse event is defined as: 
“An appreciably harmful or unpleasant reaction, resulting from an intervention 
related to the use of a medicinal product, which predicts hazard from future 
administration and warrants prevention or specific treatment, or alteration of the 
dosage regimen, or withdrawal of the product” (Edwards & Aronson, 2000). 
Randomized controlled trials (RCTs) were developed to determine the efficacy and safety 
of novel treatments for disease and are considered a gold standard in this regard. 
However, the capacity of RCTs is limited concerning what they can tell about either 
effectiveness or safety under conditions of everyday use (Cartwright, 2007). Spontaneous 
Reporting Systems such as the Federal Adverse Event Reporting System (FAERS) in the 
United States have been developed to gather data for pharmacovigilance, or the post-
marketing surveillance of drugs and other treatments (Federal Drug Administration 
Adverse Event Reporting System, 2017). However, researchers have established that 
adverse events are underreported (Alvarez-Requejo et al., 1998; Gahr, Eller, Connemann, 
& Schonfeldt-Lecuona, 2016; Hasford, Goettler, Munter, & Muller-Oerlinghausen, 2002; 
Perez Garcia & Figueras, 2011).  
Electronic Health Records have been proposed as a source of data to complement 
spontaneous reporting systems. Indeed, EHR represents a rich but imperfect record of 
                                               
2 According to International Standards Organization, an electronic health record is defined as “repository 
of information regarding the health status of a subject of care, in computer processable form” 






routine clinical practice and can be used to complement other sources of data (Hersh et 
al., 2013). The HITECH Act of 2009 mandates the “meaningful use” or secondary reuse 
of electronic health records (EHR) in research to improve public health outcomes 
(Henricks, 2011). As the bulk of data of interest are embedded in the unstructured text, it 
is necessary that these data undergo extensive text processing to make them amenable to 
computation and downstream analysis (Haerian et al., 2012; X. Wang, Hripcsak, 
Markatou, & Friedman, 2009). Another issue, one that is the focus of this dissertation, is 
that of confounding, or the presence of variables that may introduce bias if left 
uncontrolled (Brookhart, Stürmer, Glynn, Rassen, & Schneeweiss, 2010; S. Greenland & 
Morgenstern, 2001).  
Unrecognized confounding factors are a significant analytic concern that can lead 
to erroneous conclusions (S. Greenland & Morgenstern, 2001). However, if these 
covariates are identified, they may help to “explain away” spurious associations and 
facilitate detection of significant relationships. For example, a strong initial correlation 
between the medication rosiglitazone may be observed with the adverse event acute 
myocardial infarction (Dore, Trivedi, Mor, & Lapane, 2009; Florez et al., 2015). 
However, if diabetes mellitus is included as a variable, the strength of this association 
diminishes. The inclusion of the comorbidity of diabetes makes sense since rosiglitazone 
is used to treat diabetes mellitus and diabetes mellitus is a known to cause heart attacks 





treatment3 (rosiglitazone exposure) and the adverse event (acute myocardial infarction). 
Note, however, that the “causal” interpretation of confounding outlined above has only 
slowly gained traction only in the last thirty-five or so years4 (J. Pearl & Mackenzie, 
2018). This interpretation, referred to as “the principle of the common cause,” was first 
noted in 1956 in the philosophy of science literature (Reichenbach, 2012). The common 
cause principle is illustrated in Figure 1. 
 
Figure 1. Illustration of a “true confounder” (S. Greenland, Pearl, & Robins, 1999). This 
illustration demonstrates the “forking pattern” exhibited by a confounder5 on a putative 
predictor/explanatory/exposure variable (drug) and an outcome variable by an extraneous 
variable (a variable besides the exposure).  
                                               
3 Were it not for diabetes, the patient would not likely have been exposed to rosiglitazone. “To treat” is 
usually thought of as having the subject (the treatment, e.g., medication or device) exert its action (as a 
force dynamic predicate (Levin & Hovav, 2005)) upon an object (some pathological phenotype), but here it 
may be thought of in terms causation with the object exerting its influence, i.e., causing the exposure.  
4 More technically exacting definitions exist, but this explanation conveys the core of what is meant by 
“confounder” (T. J. VanderWeele & Shpitser, 2013). 
5 Greenland et al. offer this definition of confounder: “the variable is an ancestor (cause) of the outcome, 
and (2), the variable is associated with the exposure, but (3) the variable is not a descendant (effect) of the 






The exploitation of observational EHR data for research purposes necessitates a 
means to identify such confounding variables, variables that are known to affect both the 
predictor (e.g., drug or pathogen exposures, genetic variants) and the health outcome of 
interest. Such exogenous factors are unavoidable in EHR data as clinical data are not 
collected under controlled experimental conditions (Brookhart, Stürmer, et al., 2010; S. 
Greenland & Morgenstern, 2001). Unless confounding bias is mitigated, the quality of 
analysis will be suboptimal (S. Greenland & Morgenstern, 2001). One approach to 
confounding control is by identifying confounders and including them into one’s 
statistical or causal model through experience or domain knowledge. The problem of 
specifying a causal model consistent with background knowledge is referred to as the 
“identification problem” (Freedman, 2004; Han, Xie, Wu, Li, & Zhu, 2015; W. Li, Jiang, 
Geng, & Zhou, 2018; J. Pearl & Mackenzie, 2018). If more powerful methods are not 
developed to address confounding, the EHR is likely to remain an underutilized resource 
(Brookhart, Stürmer, et al., 2010; Hersh et al., 2013; Samuels, McGrath, Fetzer, Mittal, & 
Bourgoine, 2015).  
This dissertation directly addresses the identification problem of causal modeling 
within a meta-statistical causal modeling framework. Here, I emphasize “meta-statistical” 
because descriptive statistics derived from data alone are insufficient to identify 
confounders or other types of causal relationships (Amirkhani, Rahmati, Lucas, & 
Hommersom, 2016; Cooper, Gregory F., 1984; Heckerman, Geiger, & Chickering, 1995; 





Causal modeling may be thought of as a fusion method wherein assumptions from 
background knowledge are combined with empirical data (experimental, observational, 
or both) (Cooper & Yoo, 2013) to provide insight into the mechanisms responsible for 
generating inter-variable covariance patterns (Heckerman et al., 1995; Meek, 2013, 2013; 
Judea Pearl, 2009; P. Spirtes, Glymour, & Scheines, 2012).  
A universally satisfactory definition of causality eludes scholars and remains a 
topic of active research. This dissertation assumes a classic counterfactual definition of 
causality6: “were it not for X, Y would not have happened” (Beebee, Hitchcock, & 
Menzies, 2009; Hume, 1748; Lewis, 1979; Mackie & Press, 1980; Judea Pearl, 2009; 
Salmon, 1984). Relationships due to causation and probabilistic association often share 
common attributes: temporal precedence and spatial contiguity. To use an example from 
Cheng et al., a rooster may crow before dawn, but sound does not and cannot levitate 
objects7 (Holyoak & Cheng, 2011). A key distinction is that a causal relationship is by 
definition not merely necessary8, but stable under varying conditions and sufficient to 
produce an effect (Mackie & Press, 1980; Judea Pearl, 2009; Woodward, 2016).  
Given background knowledge of confounders identified in the literature9, the 
present work describes a causal modeling framework to use observational clinical data 
                                               
6 Is causality a stochastic process with deterministic surface manifestations or deterministic process with 
stochastic surface manifestations? David Hume offered not one but at least three distinct definitions of 
causality in his works (Beebee, Hitchcock, & Menzies, 2009). 
7 Per Glymour in personal note: “the rooster’s crow does levitate some objects, e.g., sleepers who hear it, 
just like a trumpet at dawn causes soldiers to rise.” 
8 Oxygen is necessary for arson to occur, but it is not sufficient. Oxygen is, however, an “enabling 
condition.”  
9 By contrast, in “causal discovery,” a closely related area of research, one may not necessarily entertain 





derived from EHR to determine the likelihood that a particular medication might cause an 
adverse event. This domain knowledge provides a “causal story” to help filter out more 
likely cause-and-effect drug/adverse event relationships from less likely drug/adverse 
event pairs that tend to frequently co-occur due to their having a common cause (J. Pearl, 
Glymour, & Jewell, 2016). The associational methods of traditional statistics can only 
indicate statistical correlation, and not determine causal relationships, yet such 
relationships are what is desired in the sciences (C. Glymour, Scheines, & Spirtes, 2014; 
Mackie & Press, 1980; Salmon, 1984).  
Before proceeding further, a necessary clarification should be made to emphasize 
the distinction between the ends of causal modeling and the evidentiary establishment of 
causal claims. Confusion remains as the selfsame word is used for both (both hypothesis 
and its establishment) and that both rest on “external validation” (Reeves et al., 2014).  
Sir Bradford Hill defined a set of criteria for establishing causal relationships in 
medicine: these criteria include prevalence, exposure, incidence, consistency, 
temporality, biological gradient, and so forth10 (Hill, 1965). The establishment of a 
causal claim is a product of consensus mediated by the scientific community and a body 
of evidence11 (Thagard, 2018). A causal claim requires explanatory coherence between 
the hypothesis and the evidence to be accepted. The elements of explanatory coherence 
                                               
10 Robert Koch in 1882 described another related set of criteria required to demonstrate causal 
relationships between microorganisms and disease, called the “Koch postulates” (Brock, 1961; Thagard, 
2018). 






include voluminous evidence of consistent biological plausible empirical data and if 
possible randomized experimentation to rule out confounding factors. By contrast, causal 
modeling cannot by itself establish a causal relationship, as this is a social process 
mitigated over time within the scientific community, and as such beyond the purview of 
the present discussion (Thagard, 2018).  
Rather, causal modeling is a tool for data-driven exploration of causal 
hypotheses. Its inputs are data and causal assumptions (including domain knowledge), 
and the output of these artifacts is a causal model, i.e., a configurable blueprint of the 
mechanisms that underlie the variables so subsumed12 (Cartwright, 2004; J. Pearl et al., 
2016; J. Pearl & Mackenzie, 2018).  
Causal modeling incurs an extra cost beyond raw data, as domain knowledge of 
confounders (or “a causal story”) facilitates its practical application and hence, the 
discernment of causal relationships (J. Pearl et al., 2016). Since it is not feasible to 
perform causal analysis without such knowledge (although the data can in fact indicate 
confounders or their absence), causal modeling at scale is not tractable without some 
means to automate the identification of contextually relevant covariates.  
One promising source of domain knowledge to populate causal models is the 
biomedical literature. If it were possible to identify confounding variables13 in the 
                                               
12 Cartwright writes: “Old causal knowledge must be supplied for new causal knowledge to be had” 
(Cartwright, 1994) 
13 Other types or “roles” of causal variables exist: mediators which lie along the causal path from an 
explanatory variable to the outcome (Richiardi, Bellocco, & Zugna, 2013; T. J. VanderWeele, 2012, 2012), 
instrumental variables which are correlated with the explanatory variable but not the outcome, to name a 





literature, this would obviate the need for manual construction of causal models by 
domain experts and hence permit the application of causal modeling and the evaluation of 
causal hypotheses at scale.  
 The primary hypothesis of this dissertation is that causal models informed 
by domain knowledge will outperform purely statistical methods for detecting 
drug/adverse event relationships in clinical data derived from EHR. To this end, this 
dissertation develops and describes a concrete application of this approach within the 
problem domain clinical research informatics (as it pertains to the secondary re-use of 
electronic health records), and more specifically to the field of pharmacovigilance. This 
approach leverages the literature to predict and identify confounders in EHR-derived data 
and uses these covariates within a probabilistic generative causal modeling framework to 
estimate the magnitude of drug/adverse event relationships. To access domain knowledge 
in the literature, this work describes techniques derived from Literature-Based Discovery 
(LBD) methods. LBD is a program of research pioneered by librarian-turned-researcher 
Don Swanson in the 1980s that focuses on identifying implicit relationships embedded in 
publicly available knowledge as a means to generate novel hypotheses14 (Bruza & 
Weeber, 2008). The intuition behind LBD, which Swanson referred to as the “A-B-C” 
model is as follows: A is associated with B and B is associated with C in the literature 
(Smalheiser, 2012, 2017). The task of LBD is to identify what “B” is, referred to as a 
“bridging term” (Hristovski, Friedman, Rindflesch, & Peterlin, 2006). In the case of 
                                               
14 More recently, LBD work has expanded into detecting of pharmacovigilance signals in the biomedical 





causal modeling for pharmacovigilance, the confounders identified in the literature derive 
from these bridging terms.  
This dissertation tests the hypothesis above with three specific aims: Aim 1 
describes the task of creating a database of clinical data derived from EHR and 
establishing a baseline using unadjusted traditional statistical methods (logistic 
regression) using a curated publicly available reference data set. Aim 2 defines a method 
to integrate the literature-identified variables into the causal graphs with a focus on the 
graph structure. Aim 3 presents a strategy to estimate average treatment effects using 
conditional probability queries on data simulated from “modified” or “mutilated” causal 
graphs.  
These aims are described in detail as follows:  
1.1 SPECIFIC AIM I: Extract clinical data from EHR and evaluate baselines scores 
using traditional statistical methods with and without confounding adjustment  
(from incorporating literature derived covariates). 
Objective: Extract clinical data from a clinical data repository after having 
attained approval from the [UTHealth] IRB, and construct a statistical baseline 
using logistic regression for comparison with causal models. 
Rationale: Create clinical data database and obtain a performance baseline for 
EHR-based pharmacovigilance for comparison with more sophisticated models 
that will incorporate literature-derived confounders. Demonstrate the feasibility 
of using LBD to identify contextually relevant confounders given a drug and an 





Research Question(s): How difficult is it to detect pharmacovigilance signals in 
EHR with traditional statistical methods (logistic regression)? Do literature-
derived confounders help to reduce confounding bias in statistical models of 
EHR data? Which discovery patterns are most effective at reducing 
confounding? Can the literature be used to identify confounders? Can the 
identified confounders be used to “explain away” spurious correlations in 
observational clinical data, thereby improving the accuracy of predictions based 
on statistical associations? 
1.1.1 Extract clinical data from EHR that will be utilized in evaluating the literature-
identified covariates. 
1.1.2 Evaluate baseline performance both with and without confounding adjustments.  
Use a publicly available reference dataset15 with EHR data by calculating the 
Area Under the Curve of a Receiver Operator Characteristic (AUROC) from the 
aggregated ranked-order logistic regression coefficients for each drug/adverse 
event pair in the reference dataset (Ryan, Schuemie, et al., 2013; UTHealth BIG., 
2017). 
1.2 SPECIFIC AIM II: Develop and test the utility of the literature-identified 
confounders in causal models and compare the results with those from statistical 
models. 
Objective: Incorporate literature-identified confounders into causal models. 
                                               
15 Reference datasets in pharmacovigilance are used for methodological evaluation of novel methods for 





Rationale: Demonstrate the utility of graph topology learned from EHR data 
within a pharmacovigilance use case, a core subfield of biomedicine. 
Research Question(s): How useful is the structure of causal graphs for 
disentangling pharmacovigilance signal from noise? What is the optimal number 
of confounding variable candidates to incorporate into a model? Is automated 
causal inference feasible using literature-based discovery as a feature selection 
technique for potential confounders? 
1.2.1 Define a method to integrate not only the literature-identified variables, but a 
causal subgraph16 of these covariates into causal models. Evaluate the utility of 
the literature-derived confounders on the task of disentangling adverse event 
signals from noise in logistic regression models of EHR data using a publicly 
available reference dataset (Ryan, Schuemie, et al., 2013; UTHealth BIG., 2017). 
1.2.2 Evaluate the utility of causal models with literature-identified confounders and 
graph structure for improving signals of causal drug/adverse drug event 
relationships. 
1.2.3 Evaluate the utility of causal models with literature-identified confounders and 
graph structure for improving signals of causal drug/adverse event relationships. 
Use a publicly available reference set with EHR data by calculating the AUROC 
from the aggregated ranked-order logistic regression coefficients for each 
                                               
16 “Causal subgraph” refers to the directed acyclic graph (which consists of nodes and directed edges, or 
arrows) wherein domain knowledge facilitates the orientation of the edges of the literature-derived 






drug/adverse event pair in the reference dataset (Ryan, Schuemie, et al., 2013; 
UTHealth BIG., 2017). 
 
1.3 SPECIFIC AIM III: Develop and test methods to estimate Average Treatment 
Effect (ATE) from simulations using causal models informed by literature-derived 
confounders. 
Objective: Incorporate literature-identified confounders into causal models and 
estimate treatment effects using simulated data from the topology and structures 
learned from the EHR data.  
Rationale: Demonstrate the generalizability of causal models with the automatic 
selection of literature-derived confounders using another set of clinical data derived 
from EHR and another reference dataset (Rave Harpaz, 2014). 
Research Question(s): How useful is parameter estimation17 for reducing error? Is it 
possible to calculate average treatment effect? 
1.3.1 Develop the data generating process capabilities of causal models and exploit 
these simulations to estimate Average Treatment Effect (ATE). Evaluate methods 
using a publicly available reference set with EHR data by calculating the AUROC 
from the aggregated ranked-order logistic regression coefficients for each 
drug/adverse event pair in the reference dataset (Ryan, Schuemie, et al., 2013; 
UTHealth BIG., 2017). 
                                               
17 “Parameter estimation” refers to estimating the strength of the causal relationship that is inferred 





The research domains addressed by this thesis include literature-based discovery, 
causal modeling and discovery, and pharmacovigilance methodology. Natural language 
processing (NLP) facilitates this work but is not the theoretical focus. The literature-
based discovery research paradigm is used as a means of accessing salient domain 
knowledge given a problem space defined by cue terms (a drug and an adverse event). 
The use of LBD methods to identify confounding variables is a novel application of these 
methods. Literature-based discovery in our configuration harnesses semantic constraints 
in the form of predicates to identify salient covariates for our models. In the approach, 
literature-based discovery is used to automate feature selection combined with constraints 
on the directed acyclic graphs in our causal models.  
The contributions of this thesis to the discourse of biomedical informatics are as 
follows:  
1. Demonstration of a novel domain of application for LBD methods.  
2. Demonstration of LBD methods to automatically identify confounding 
variables and improve the accuracy of predictive models (both classical 
statistical and contemporary causal modeling methods).  
3. Demonstration of how domain knowledge may be used as a means to 
constrain hypothesis space and automatically devise hypothetical 
explanations of empirical observational data. The automated generation of 
hypotheses to explain observations using domain knowledge is tantamount 





silico (Dziurosz-Serafinowicz, 2012; Gabbay & Woods, 2005; 
Reichenbach, 2012).  
4. The methods proposed may be generalized to other areas of biomedicine. 
For example, these methods may be adapted to identify control groups for 
RCTs (Fokkema, Smits, Zeileis, Hothorn, & Kelderman, 2017). 
As a desirable bonus feature, the graphs that result from the approach should be 
clinically insightful. Interpretability being a notable feature of our approach, clinicians 
may use the graphs to enhance their comprehension of the underlying pathophysiology, 
inspire unexpected questions, or discern potential risk factors when considering a course 
of treatment, thereby improving health outcomes.  
This dissertation is organized as follows. Chapter 2 reviews previous work in 
EHR-based pharmacovigilance, identify methodological gaps and provide the 
background and motivation for understanding the impetus for refashioning the literature-
based discovery framework to inform causal models using EHR-based observational 
clinical data as a primary data source. Chapter 3 presents an overview of literature-based 
discovery and causal modeling components and how they complement each other. 
Chapter 4 tests Specific Aim 1 by incorporating the confounding variable candidates 
identified in the literature into logistic regression models. Chapter 5 and Chapter 6 
implement and evaluate variants of the causal modeling, and discuss their implications 
for the secondary analysis of observational data (addressing Specific Aim 2 and 3). 





theory of informatics, discusses the limitations of the present study, and presents 






Chapter 2: Literature Review 
There are also a number of things for which it is not enough to name one cause, 
but many, one of which is nevertheless the true cause: just as if you should 
yourself see some man’s body lying lifeless at a distance, you may perhaps think 
proper to name all the causes of death in order that the one true cause of the 
man’s death be named. For you could not prove that steel or cold had been the 
death of him, or disease, or it may be poison, but we know that what has 
happened to him is something of this sort.  
 Lucretius, De Rerum Natura, 6.703 – 709 
 
This chapter provides an overview of related work in pharmacovigilance, causal 
inference, and literature-based discovery. To circumscribe the scope of the current 
review, unresolved challenges of using clinical text derived from electronic health record 
(EHR) systems for pharmacovigilance will be presented first. Noting the unresolved 
challenges will help to specify the problem, and thereby isolate the gaps in the current 
literature, that this dissertation seeks to address.  
2.1 Pharmacovigilance  
Some 770,000 adverse events occur annually in the United States alone, resulting 





systems worldwide18 (Diaz-Garelli, Bernstam, Mse, Rahbar, & Johnson, 2015; Hersh et 
al., 2013). Pharmacovigilance aims to address the set of challenges posed by adverse 
events, including those detected after drugs are released to market after regulatory 
approval. It seeks to ascertain the risks and benefits of exposure, identify 
contraindications, and in extreme cases withdraw products altogether in the event of 
severe adverse events19 (J. K. Aronson, 2017). Recognizing the need to monitor adverse 
effects of drugs systematically, since surveillance cannot and does not end after approval, 
regulatory agencies such as the US Food and Drug Administration (FDA) have 
implemented spontaneous reporting systems, through which clinicians and administrators 
of clinical trials can report potential adverse events as they are observed. However, 
spontaneous reporting systems such as the Federal Adverse Event Report System 
(FAERS) have limitations, including incomplete clinical information, under-reporting of 
side-effects, and unacknowledged sources of bias (Alvarez-Requejo et al., 1998; Federal 
Drug Administration Adverse Event Reporting System, 2017; Hasford et al., 2002).  
Researchers in pharmacovigilance have sought to evaluate the utility of other 
sources of data as input for pharmacovigilance methods. These have included both 
structured and unstructured data and from social media, claims data, and clinical data 
derived from electronic health record (EHR) systems (Edlinger et al., 2014; Eshleman & 
Singh, 2016; Haerian et al., 2012; Rave Harpaz et al., 2017; Rave Harpaz, DuMouchel, & 
                                               
18 In one UK study, adverse events resulted in ~ 6.5% of all hospital admissions (Pirmohamed et al., 
2004). 
19 For a historical introduction to the history of pharmacovigilance from the case of thalidomide which led 
to the passage of the Kefauver-Harris Act of 1962, and the Vioxx case, see (Nesi, 2008; “News & Events > 





Shah, 2015; Hersh et al., 2013; Y. Li et al., 2014; Lin & Schneeweiss, 2016; Liu, Zhao, & 
Zhang, 2016; Pierce et al., 2017; Samuels et al., 2015; X. Wang et al., 2009). The focus 
of this dissertation is on the use of unstructured clinical text recorded in EHR systems.  
Clinical text (notes) recorded in EHR systems are a potentially useful source of 
data for pharmacovigilance, yet drawing reliable conclusions from routinely collected 
clinical data is notoriously challenging (Diaz-Garelli et al., 2015; Hersh et al., 2013). In 
the pharmacovigilance literature, the term “signal” refers to anything that warrants further 
investigation. Signals may be easier to detect in clinical trials where subjects are 
deliberately monitored for side-effects, by contrast data embedded clinical narratives 
were not collected for pharmacovigilance, and are often beset with redundancy or 
missing data, use of non-standard abbreviations, misspellings, and so on. In addition, 
clinical data contain confounding variables (Hersh et al., 2013; Y. Li et al., 2014).  
2.1.2 Confounding in Electronic Health Records  
An association between two variables, let’s denote them X and Y, cannot be 
explained with reference only to themselves (Wasserman, 2013). One needs to introduce 
at least one other variable, and usually many other such covariates, to rule out non-causal 
reasons for an observed statistical correlation. If one were to possess domain knowledge 
of X and Y, one might include a third variable Z that experience or domain knowledge 





of their co-occurrence (referred to as the principle of the common cause)20 (Reichenbach, 
2012). For example, there may be a robust initial correlation between a drug, e.g., 
rosiglitazone, and myocardial infarction. However, upon the introduction of the third 
variable of diabetes, which rosiglitazone is used to treat and which also is known to cause 
heart attacks, the robust initial correlation is diminished. The identification of such 
covariates may be acquired either through analysis of the data itself or by experience or 
domain knowledge (Y. Li et al., 2014a). Given such knowledge, the determination of the 
existence and/or magnitude of the effect of X on Y may be measured in one of two ways:  
1.) By a randomized experiment, with samples chosen for similar risk 
characteristics, e.g., those who are carriers of an allele associated with risk of developing 
a disease or family history.  
2.) From non-experimental observational data that infer the influence of latent 
confounding or with the inclusion of such covariates into statistical and/or causal models 
as shall subsequently be described.  
Experimental conditions are by all means preferred when possible since the 
researcher may carefully control the introduction of exogenous or independent variables  
to measure the outcome and determine the existence and magnitude of any causal 
relationship. However, the opportunity and the advantages of such conditions may not 
always be feasible: randomized control trials may be unethical to obtain or intractably 
                                               
20 The Principle of the Common Cause does not always hold: correlation may be present in the 





expensive, e.g., studying the relationship between tobacco use and lung cancer (Kovesdy 
& Kalantar-Zadeh, 2012). This brings us to the focus of this dissertation: the 
determination and estimation of the risk of adverse events arising from the exposure to 
medications using non-experimental data, specifically observational clinical data derived 
from unstructured clinical text (notes) in electronic health records 21.  
The following section will discuss study designs of related work in 
pharmacovigilance using clinical data derived from electronic health records within the 
context of confounding.  
2.1.2.1 Confounding control  
If individual variables exogenous to but influencing an X and a Y of interest may 
be identified and have been measured, it may be possible to determine the existence of a 
relationship and/or estimated measure of the risk of an adverse event given exposure 
from observational data under certain conditions (C. Wang, Dominici, Parmigiani, & 
Zigler, 2015; G. Wang, Jung, Winnenburg, & Shah, 2015; X. Wang et al., 2009). 
Researchers have developed a convenient taxonomy for the various types of confounder 
that may be present in electronic health records for pharmacovigilance. These include 
confounding by co-morbidity, confounding by co-medication (where exposure to another 
drug is responsible for producing the adverse event), and confounding by indication 
                                               
21 As noted in Chapter 1, other forms of non-experimental observational data, e.g., claims and social media 





(wherein complications from the disease being treated may be culpable for producing the 
adverse event) (Y. Li et al., 2014a).  
 
2.1.2.2 Confounding and Confounders  
Confounding is present when the influence of common causes, alternate 
etiologies, or uncontrolled latent variables introduce bias in one’s model (Judea Pearl, 
2009; T. J. VanderWeele & Shpitser, 2011, 2013). The term “confounding” is the more 
generally accepted word for the overarching phenomenon that denotes bias endemic to 
observational data, while the term “confounder,” which refers to an individual variable 
that introduces confounding, has only recently gained acceptance and traction among 
researchers (T. J. VanderWeele & Shpitser, 2013). Etymologically, confounding refers to 
a state of being mixed up or confused (“confound | Definition of confound in English by 
Oxford Dictionaries,” n.d.).  
If a confounder can be identified, then it may be incorporated into one’s model to 
de-confound that model and reduce confounding and hence potentially improve the 
quality of one’s analysis. Insofar as it reduces bias due to confounding, it is a proper 
confounder (S. Greenland et al., 1999; Judea Pearl, 2009; T. J. VanderWeele & Shpitser, 
2013). However, if such a covariate does not serve to improve the model, then it should 
be ignored, a condition that is referred to as “ignorability” (S. Greenland & Morgenstern, 







2.1.2.3 Selection Bias, Measurement Error, and Confounding22  
 Since observational clinical data were not produced under experimental 
conditions, other types of bias may be present. These may include selection bias and 
measurement error (Haneuse, 2016; Talbot & Aronson, 2012). Selection bias occurs 
when a sample of individuals for a study is not properly randomized23 and is therefore not 
representative (Haneuse, 2016; Miguel A. Hernan, Hernandez-Diaz, & Robins, 2004). 
For example, particular practices may have self-selected for patients that could be 
particularly vulnerable to an adverse event. Additionally, errors may be introduced in 
measurement in data collection as a result of typographical errors or other factors, such as 
clinician fatigue or burnout (Collier, 2017; EHRIntelligence, 2018; Wachter & 
Goldsmith, 2018). However, however methods to control these other sources of bias are 
beyond the scope of this dissertation and have been addressed elsewhere (Cartwright, 
2004; Elwert & Winship, 2014; Haneuse, 2016; Miguel A. Hernan et al., 2004; P. H. Lee 
& Burstyn, 2016; Suzuki, Tsuda, Mitsuhashi, Mansournia, & Yamamoto, 2016). Instead, 
this dissertation focuses on the prospect of controlling exogenous variables that may be 
identified in the clinical text. The next section describes methods to control for 
confounding either through analysis of the data or by other means, such as the application 
                                               
22 I acknowledge that I am excluding missing data bias, reporting bias, design bias, protophatic bias, 
clinician facility bias, clinical NLP bias, and so on. 
23 Glymour in personal note: “randomization does not guarantee representativeness, nor does absence of 





of background knowledge extraneous to the raw data inputs to inform structural causal 
models (the focus of this dissertation).  
 
2.2 Related Work: confounding control in EHR-based pharmacovigilance 
 Confounding control in observational data study designs may be categorized by 
two general classes: control by design (e.g., cohort studies, case-control) and control by 
analysis (Talbot & Aronson, 2012).  
2.2.1 Control by Design  
Cohort and case-control models are two methods that have been proposed to 
address confounding in EHR data that can be characterized by “control by design” 
(Talbot & Aronson, 2012). Similar to RCTs, subgroups are identified and included in 
these studies for their respective populations having similar risk factors and other 
characteristics “with the purpose of mitigating the effects of confounders” (Lewallen & 
Courtright, 1998). A primary difference between case-control and cohort studies is that 
case-control studies are retrospective and cohort studies are prospective (Lanza, Ravaud, 
Riveros, & Dechartres, 2016; Pugh, Bronsvoort, Handel, Summers, & Clements, 2014; 
Talbot & Aronson, 2012, p. 376). Such study designs are notable for producing accurate 
and useful results at detecting and verifying adverse events given exposures, particularly 
rare drug/adverse event relationships, but may be susceptible to selection bias 
(Backenroth, Chase, Friedman, & Wei, 2016; de Bie et al., 2015; Lanza et al., 2016; 





studies excel at detecting rare events (Pugh et al., 2014). However, it is important to point 
out an important limitation: such study designs are not informative about risk factors, 
enabling conditions, contraindications, and alternate etiologies that can help to explain 
the nature of an alleged drug/adverse event relationship. Furthermore, in observational 
data there is always the risk of unobserved and unmeasured covariates.  
2.2.2 Control by Analysis  
Control by analysis implies the application of statistical techniques to identify 
covariates to control for confounding from data or background knowledge. One research 
tack in confounding control in EHR-based pharmacovigilance has focused on using the 
data to identify individual confounders (Backenroth et al., 2016; Y. Li et al., 2014). Li et 
al. recently developed a method to identify confounders in data. Li used a propensity 
score method (PSM) (Tatonetti, Ye, Daneshjou, & Altman, 2012) to identify factors 
associated with the treatment and another technique to identify risk factors associated 
with the outcome (R. Harpaz et al., 2012). An overlap between these two sets (of the 
“comorbidity” subtype in pharmacovigilance) were collected. Li processed subsets of 
these data-derived confounders using penalized regularization methods, specifically lasso 
regression (Y. Li et al., 2014). Lasso regression is a regularization and variable selection 
technique that shrinks multivariate predictor coefficients that fall beneath a threshold 
down to zero (Tibshirani, 1996). However, Least Angle Regression (LAR), the algorithm 
that is most commonly used to perform lasso regression, can be computationally 
expensive, depending on input, being either quadratic 𝑶(	𝒏 𝟐 ) or cubic 𝑶(	𝒏 𝟑 ) in 





produced improvements in this regard (Efron, Hastie, Johnstone, & Tibshirani, 2004; J. 
Friedman, Hastie, & Tibshirani, 2010; N. Simon, Friedman, Hastie, & Tibshirani, 2011).  
Using these methods, Li reported a precision of 83.3% (95% CI: 62.2% to 100%) 
for rhabdomyolysis and 60.8% (95% CI: 47.4% to 74.2%) for pancreatitis. These scores 
improved upon scores and confidence intervals using either risk factors or PSM scores 
alone. Li noted that having a sufficient number of samples is critical to decreasing the 
number of false negatives, as many adverse events are rare. 
2.2.2.1 Disproportionality Metrics 
Disproportionality metrics are a traditional method of detecting drug/adverse 
event relationships in SRSs. These include Odds Ratio, Reporting Odds Ratio (ROR), 
and Reporting Risk Ratio (RRR). As these metrics are derived from the occurrence 
statistics of pairs of entities (without addressing other [potentially confounding] entities), 
these techniques were found to have little utility in terms of either sensitivity or 
specificity for EHR data (DuMouchel, Ryan, Schuemie, & Madigan, 2013; Ryan, Stang, 
et al., 2013).To account for sampling bias and differences between sample size, to 
increase sensitivity to rarer adverse events, the Multi-item Gamma Poisson Shrinker 
(MGPS) was developed and is currently in use by the United States Food and Drug 
Administration (FDA) (Commissioner, n.d.; Rave Harpaz et al., 2013). Longitudinal 
Gamma Poisson Shrinker (LGPS), a variation of MGPS, has been applied to claims and 









2.2.2.2 Meta-analytic methods 
Other innovative signal detection approaches have involved combining multiple 
data sources (including at times “omics” data) via meta-analysis (Evans, Chaix, 
Lobbedez, Verger, & Flahault, 2012; Y. Li, 2015; Oliveira et al., 2013; G. Trifiro et al., 
2014). Li was able to achieve 0.73 overall AUROC by combining EHR with FAERS data 
(improving AUROC of the EHR by 0.22 from the overall baseline of 0.51) (Y. Li, 2015). 
However, these techniques insofar as they apply to the detection of drug safety signals in 
EHR belong arguably to a higher ontological order of pharmacovigilance – that of 
substantiation and validation (Bauer-Mehren et al., 2012; Talbot & Aronson, 2012; 
Gianluca Trifiro, Sultana, & Bate, 2018). Meta-analysis has the potential to improve the 
performance of any individual method to the extent that it can be applied to multiple data 
sources. 
2.2.2.3 Other common methods 
Other regression and regularization based methods have been applied to EHR 
systems, including propensity scores – wherein the characteristics of a large set of 





received a treatment (Rave Harpaz et al., 2015; Madigan, Ryan, & Schuemie, 2013; 
Rosenbaum & Rubin, Donald, 1983). Ideally, the treated and untreated subgroups should 
have similar characteristics. However, Ali et al. and Jackson report that the selection of 
covariates that are used in studies that that use the PSM rarely report their covariates or 
how they came to chose them (Ali et al., 2015; Jackson, Schmid, & Stuart, 2017). 
There exist hybrid methods as well, e.g., recent research incorporating 
confounders from enriched data (Backenroth et al., 2016). Data enrichment refers to the 
utility of introducing relevant evidence to a problem of interest to contextualize and 
understand it (Boyce et al., 2014).  
The question remains: what is the best way to integrate these data, this 
information, this knowledge? Associational studies using traditional statistics offer only 
descriptions of data, yet a critical component of what science desires is a means to derive 
insight into mechanisms and interrelationships. The next section describes work that has 
the means to peer beyond the associational approach.  
2.2.2.4 Causal inference methods  
 The objective of causal inference is to estimate the likelihood of one variable 
producing a change in another under varying conditions and may be thought of as “the 
counterpart to experiment” for observational data (Ranganath & Perotte, 2018).To date, 
most work that has been done with causal inference methods in the field of 
pharmacovigilance have been in application of instrumental variables (Brookhart, 
Rassen, & Schneeweiss, 2010; Brookhart, Wang, Solomon, & Schneeweiss, 2006; 





is chosen for fulfilling two criteria: 1.) it should not share a mutual cause with the 
outcome (in this case, an adverse event), and hence is unconfounded with it; and 2.) it 
should be correlated strongly with the explanatory variable, or estimator (in this case, a 
drug) (S. Greenland, 2000).  
An example of an instrumental variable that has been used in a pharmacovigilance 
study would be the inclusion of a variable that represents the attending clinician, since 
physicians may tend to be partial to the medications that they prescribe. However, 
controversy exists over the validity of such variables (Brookhart et al., 2006). One meta-
analysis of instrumental variable studies found that only 16/28 offered empirical evidence 
that their choice of instrument fulfilled both criteria (Chen & Briesacher, 2011). Other 
examples of instrumental variable types included patient history, financial status, and 
calendar time. The intuition that underlies instrumental variables is that the instrument, 
e.g., patient income, may be thought of as a “cue ball” in a game of billiards, where that 
ball is struck by the player and is used strategically to propel other balls into the pockets 
of the gaming table. If the instrumental cue ball is correlated with the outcome (the 
adverse event), the causal effect of the candidate cause may be estimated with a simple 
ordinary least squares regression (OLS) or two state least squares24 (Bowden & 
Turkington, 1985; S. Greenland, 2000). Instrumental variables may be thought of as side-
stepping the issue of identifying individual confounders, since instrumental variables may 
be used to estimate effects “even in the presence of unmeasured common causes” 
                                               





(confounders)25 (Chu, Scheines, & Spirtes, 2013). One recent exception to the focus on 
instrumental variables in pharmacovigilance explicitly addresses the issue of 
confounding, but the method described sidesteps the issue of identifying confounders by 
inferring the magnitude of shared confounders between independent treatment regimes 
and estimating upper and lower bounds for the influence of the latent (and unidentified) 
confounders (Ranganath & Perotte, 2018).  
The causal modeling techniques presented above excels in the case when there is 
hidden latent and/or unmeasured confounding as no knowledge of covariates is required 
and so the covariates it follows do not have to be measured26 (Ali et al., 2015). Indeed, 
many of the methods that have been reviewed thus far are agnostic of covariates. What 
happens if we have rich though flawed EHR data extracted from narrative text: a case in 
which many individual confounders may have been measured? One promising source of 
knowledge that may be exploited to identify potentially relevant covariates is the 
literature. 
2.4 Literature-Based Discovery 
A fundamental limitation of the approaches mentioned above is that etiological insights 
into confounders, risk factors, and enabling conditions that are present in the literature 
may be amiss in the analyses of researchers. Absent the identification of exogenous 
                                               
25 Semi-instrumental variables wherein the non-confounding assumptions concerning the 
outcome of interest are weakened may be used as estimators given that common causes 
between the instrument and the outcome are controlled for and measured (Chu, Scheines, & 
Spirtes, 2013). 
26 Koller likens such methods to modelling a process of, to paraphrase, all latent background 





variables in observational data, researchers may not be able to take full advantage of 
EHR data. Since EHR is so rich, might it be possible to identify confounders and control 
for them in observational data so as to gain additional insight?  
Traditionally, statisticians have depended upon the domain knowledge elicited 
painstakingly from domain experts to identify relevant confounding factors (Y. Li et al., 
2014). While this approach to gathering background knowledge is likely to result in the 
identification of confounding variable candidates pertinent to an individual study, it 
would be financially intractable to hire the quantity and diversity of experts needed to 
conduct pharmacovigilance across large numbers of marketed drugs and each of their 
potential adverse events.  
The focus of literature-based discovery has historically been on the identification 
of novel therapies. Literature-based discovery methods have recently been utilized to 
assess the plausibility of drug/adverse event associations (Cohen & Widdows, 2017; 
Hristovski et al., 2006; Mower, Subramanian, Shang, & Cohen, 2016; Shang, Xu, 
Rindflesch, & Cohen, 2014). As literature-based discovery has not traditionally been a 
paradigm to interoperate with observational data, the current work represents a novel 
problem domain for literature-based discovery methods, where such methods are 
repurposed to identify confounders in observational data for adjustment. 
2.5 Summary 
The gap the current work addresses is the lack of methods tools to LBD-informed 





sets of confounding variable candidates that have been observed in the literature can be 
used to identify concepts that reflect this “causal story” for the task of confounding 
adjustment of clinical data derived from EHR. The data-driven, knowledge-based method 
described aims to find a middle ground between human-intensive expert-guided 
confounding variable discovery and computationally intensive selection of such variables 
based on empirical data alone. The following chapter provides an overview of literature-
based discovery methods of identifying such a causal story with which to populate 






Chapter 3: Methodological Framework 
This chapter explains the core components of the approach developed and tested in this 
dissertation (causal modeling and literature-based discovery), and then provides 
theoretical context to understand how these components complement each other.  
Causal Modeling and Literature-based Discovery: a Synthesis. The method 
developed uses the literature to identify contextually relevant variables to include in 
statistical and/or causal models as a means to control for confounding bias in 
observational clinical data derived from EHR. This chapter leaves out some specifics, 
e.g., version of SemMedDB used, which Discovery Patterns, the advanced methods for 
estimate the Average Treatment Effect (ATE) (described in Chapter 6). Such specific 
details of the experiments will be described and clarified in the chapters to follow.  
3.1 Overview of Causal Modeling 
In recent decades, causal inference methods have been developed by such seminal figures 
as Judea Pearl, Gregory Cooper, and Clark Glymour (Cooper, Gregory F., 1984; Judea 
Pearl, 2009; P. Spirtes et al., 2012; Peter Spirtes & Glymour, 1991). The patrimony of the 
field of causal modeling is remarkably diverse and interdisciplinary. The fields that have 
contributed to causal inference include the following: its epistemological basis 
(philosophy of science), potential outcomes framework and path diagrams (agronomy 
and genetics) (“Corn and hog correlations / by Sewall Wright. v.1300(1925). - Full View 





Iwaszkiewicz, & Kolodziejczyk, 1935; Rubin, 1990; S, 1921), structural equation models 
(economics and the social sciences) (A, 1990; “CFM 14 | Cowles Foundation for 
Research in Economics,” n.d.; Duncan, 1975; Goldberger & Duncan, 1973; Haavelmo, 
1944; J, 2008), counterfactual analysis (philosophy) (Cartwright, 2007; C. N. Glymour, 
2001, 2001; Hume, 1740, 1748; Lewis, 1979; Mill, 1843; Scheines, Spirtes, Glymour, 
Meek, & Richardson, 1998), computational tractability (computer science and cognitive 
science) (Gabbay & Woods, 2005; Gopnik et al., 2004; Griffiths, Sobel, Tenenbaum, & 
Gopnik, 2011; Griffiths & Tenenbaum, 2005; Holyoak & Cheng, 2011, 2011; Judea 
Pearl, 2009). While an exhaustive review of the field is beyond the scope of the present 
discourse, I will provide historical details when it may prove insightful or for 
clarification.  
The objectives of causal inference are manifold. One researcher may wish to specify the 
data generating process responsible for a set of observations to understand the underlying 
mechanisms. Another objective might be to provide insight into how to weigh policy 
options or risk/benefit factors when considering an intervention, e.g., the effects of 
raising the rate of interest on employment, or choosing between chemotherapy or surgery 
(J. Pearl & Mackenzie, 2018; Judea Pearl, 2009). Exact causal inference has been shown 
to be NP-hard27; however, causal inference from data may be approximated (Gavril, 
1977; Heckerman et al., 1995; Koller, Friedman, & Bach, 2009; Marco Scutari, Vitolo, & 
Tucker, 2018).  
                                               





The causal graphs (also referred to as “causal Bayesian networks”) and the potential 
outcomes (also referred to as the counterfactual intervention) framework have been 
synthesized into a coherent discourse only in the recent past several decades28 (M.A. 
Hernan & Robins, 2017; Morgan & Winship, 2015; J. Pearl & Mackenzie, 2018; Judea 
Pearl, 2009). Researchers realized that causal graphs and counterfactual approaches are 
essentially different languages for emphasizing and expressing aspects of the same core 
underlying ideas, with each suited for the sub-tasks for which they were initially devised 
(Morgan & Winship, 2015; J. Pearl & Mackenzie, 2018; Judea Pearl, 2009). These core 
tasks of causal modeling are the following: inferring causal graph structures (qualitatively 
determining which variables influence each other), quantitatively estimating relative 
strength of such relationships encoded in the graph, and predicting how the variables 
subsumed in such models might behave under perturbation. 
Causal inference requires additional assumptions (although these can be 
tempered): faithfulness, the causal Markov condition, and absence of latent confounders 
(the latter will be defined and explained in the next section). Faithfulness assumes that 
the causal graph represents valid dependency or causal relationships (J. Ramsey, Zhang, 
& Spirtes, 2012; Uhler, Raskutti, Bühlmann, & Yu, 2013; Zhang & Spirtes, 2012). The 
causal Markov condition describes how parent nodes in a DAG define child nodes. The 
intuition behind this is that sans quantum entanglement or “spooky action at a distance,” 
causal relations tend to be spatially and temporally contiguous. Finally, there is the 
                                               
28 Contention remains about whether or not these two frameworks have been reconciled, however. At there 
remain two camps: those who use graph search vs. the potential outcomes (where the predictor and an 





assumption of the absence of latent confounding29. That is to say that it is assumed that 
the model includes all relevant mutual causes and influences. Other perils exist for the 
would-be causal modeler: for example, selecting confounders that are themselves 
confounded, and “over-controlling” for confounding (Elwert & Winship, 2014; M.A. 
Hernan & Robins, 2017; Morgan & Winship, 2015; Judea Pearl, 2009).  
Structure Learning. There are two main algorithm classes for identifying 
graphical structures that are compatible with input data. These are constraint-based and 
score-based learning algorithms. Constraint-based learning entails a search for 
dependency relationships between input data representing nodes in a graph. If two nodes 
are independent (their correlation falls beneath a threshold), then no edge is detected 
between them (correlation is a necessary but insufficient pre-condition for a causal edge). 
The most famous constraint-based causal structure learning algorithm is the “PC” 
algorithm, first developed by Peter Spirtes and Clark Glymour (Peter Spirtes & Glymour, 
1991). Another is the Fast Causal Inference (FCI) algorithm (Scheines et al., 1998; Peter 
Spirtes & Zhang, 2016; Zhang, 2008). 
Score-based algorithms on the other hand stochastically add, delete,  orient edges, 
and optimize for a fitness criterion, e.g., Bayesian Information Criterion, wherein the loss 
function is minimized between the model and the data. Examples of these include the 
Fast Greedy Equivalency Search (FGeS) algorithm (J. D. Ramsey, 2015), derivative of 
Chickering and Meek (Chickering, 2015). Score-based algorithms are typically more 
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efficient than those which are constraint-based since they do not perform an exhaustive 
search. While score-based methods excel in computational efficiency and are easily 
parallelized, they are often poor at detecting latent variables (J. D. Ramsey & Malinsky, 
2016; Zhang & Spirtes, 2012). Hybrid structure learning algorithms exist as well. Most 
notable among these would be Greedy Fast Causal Inference (GFCI), which first runs 
FGeS and then prunes edges with a constraint-based structure learning algorithm 
(Ogarrio, Spirtes, & Ramsey, 2016; J. D. Ramsey & Malinsky, 2016; TETRAD, 2017). 
Parameter estimation and the quantification of estimated treatment or causal effects are 
addressed in Chapter 6.  
The output of most score-based causal structure learning algorithms is a set of directed 
graphs with the observed variables as vertices and is known as a completed partially 
directed acyclic graph (also called a “pattern”), or CPDAG. A CPDAG describes a family 
of graphs which are score-equivalent (Geiger, 1990; Ogarrio et al., 2016; Judea Pearl, 
2009; P. L. Spirtes, 2013). That is, based on the input data, the structure learning 
algorithm cannot specify a unique form of a graph as there may be latent variables (Chu 
et al., 2013; Geiger, 1990; P. L. Spirtes, 2013). In the case of a CPDAG, this means that 
some edges may be bi-directed. However, given domain knowledge, many of these edges 
can be oriented. If a known confounder is introduced, for example, directed edges should 
be oriented toward both the predictor or explanatory variable and the outcome. The next 
subsection discusses how confounder variable candidates are identified in the literature.  





Literature-based Discovery (LBD) is an idea first developed by Don Swanson as a means 
of using the biomedical literature to investigate therapeutically useful associations 
(Smalheiser, 2017; Swanson, 1988, 1989, 1989). Swanson's approach involves examining 
latent relationships between concepts that may suggest undiscovered therapeutic 
relationships. More recently, LBD researchers have explored the idea of using semantic 
constraints to reduce the search space of relevant associations (Bruza & Weeber, 2008; 
Hristovski et al., 2006). For example, the following discovery pattern describes a set of 
semantic constraints with which to identify a set of concepts: "drug INHIBITS x; x 
CAUSES disease." The variable “x,” referred to as a “bridging term,” may indicate a 
confounding concept that is associated with a drug and an adverse event. An example of a 
bridging term would be a term that appeared in Don Swanson’s original research in LBD: 
Eicosapentaenoic acid, or EPA, an ingredient in fish oil. Swanson noticed that the 
mechanisms that underlie the pathology of those who suffer from Raynaud disease are the 
opposite of the changes that are produced by consuming fish oil, e.g., decreased vs. 
increased blood viscosity (Swanson, 1986). In this way, Swanson was able to identify a 
novel therapy for Raynaud’s disease and proceeded to identify other potential therapies 
(Swanson, 1988, 1989). These patterns of relationships are known as “discovery 
patterns” (Hristovski et al., 2006).  
While discovery patterns have been used to identify therapeutic and harmful 
relationships previously, their application to identify confounding variables for causal 





required to make LBD scalable. The next section will address such computational 
considerations.  
3.2.1 Predication-Based Semantic Indexing (PSI) 
Recent work in the area of discovery pattern-based LBD has leveraged high-dimensional 
vector space representations derived from large (tens of millions) repositories of concept-
by-predicate-by-concept triples30 (known as semantic predications – e.g., x INHIBITS y) 
to facilitate efficient search and accurate inference, using a technique called Predication-
based Semantic Indexing (PSI) (Cohen, Schvaneveldt, & Rindflesch, 2009; Cohen, 
Widdows, Schvaneveldt, Davies, & Rindflesch, 2012). Vector Space Architecture (VSA) 
theory provides the infrastructure for PSI (Gayler, 2004; Levy & Gayler, 2008). After the 
imposition of a reversible vector transformation to encode the nature of a relationship 
connecting two concepts, these elemental vectors can be superposed upon each other to 
generate composite semantic structures called semantic vectors (Cohen et al., 2009; 
Cohen, Schvaneveldt, & Widdows, 2010; Cohen, Whitfield, Schvaneveldt, Mukund, & 
Rindflesch, 2010; Cohen, Widdows, Schvaneveldt, & Rindflesch, n.d.; Kanerva, 
Kristoferson, & Holst, 2000; Widdows & Cohen, 2015).  
3.2.2 PSI and for identifying confounding variable candidates 
PSI uses random vectors. These random vectors are an effective way to represent 
elemental components, since there is a high probability of mutual near-orthogonality in 
                                               
30 Predications are relationships in which pairs of concepts are connected by predicates (or “verbs”, e.g., 






higher dimensions. Semantic vectors, on the other hand, are composed as superpositions 
of the “bound products” of the aforementioned elemental vectors of predicate-argument 
pairs (as extracted from the literature using SemRep) (Kanerva, 1994; Kanerva et al., 
2000). The binding operator, which varies in implementation across VSAs, is a 
multiplication-like operator that provides the means to encode additional information, 
such as the nature and context of a relationship, into the resulting vector space. Since the 
same predication can be encountered in multiple documents, PSI can be thought of as a 
distributional model of predications. Critical to PSI, semantic representations of concepts 
are built up as vectors from relations found in the literature. PSI facilitates the rapid 
search for, and retrieval of, concepts that are related to one another in particular ways 
(i.e., through particular predicates). As such a space is distributional, concepts in which a 
relationship of interest occur more frequently will be retrieved first (analogous to the way 
in which other information retrieval systems facilitate ranked results). In the current 
work, PSI is used to facilitate rapid retrieval of concepts related to other concepts along 
discovery patterns that suggest potential confounders. PSI can be used to retrieve the 
most strongly associated concepts (called “bridging terms”) across any particular 
predicate discovery pattern of interest and even identify novel discovery patterns 
themselves (Cohen et al., 2012). A discussion of predicate discovery patterns that 
indicate discovery patterns will follow. PSI and its other applications are discussed in 
detail elsewhere (Cohen, Schvaneveldt, et al., 2010, 2010; Cohen et al., 2012; Widdows 





The operative assumption is that if plausible therapeutic relationships in a 
knowledge base of biomedical literature (which has arguably been the primary focus of 
work in LBD to date), then semantic constraints may be used to identify common causes 
and exploit the common cause principle. Since LBD uses distributional semantics, such 
concepts that are identified in the literature may be predictive of entities that tend to co-
occur with drug/adverse event pairs of interest in observational clinical data. 
Confounding variable candidates may be identified by matching the pre-defined 
relationship-types encoded by discovery patterns. In the next section the question of how 
the structure suggested by discovery patterns can inform the construction of causal graphs 
instantiated with EHR data. 
3.3 Framework for LBD-informed Statistical and Causal Modeling 
This section discusses how literature-derived confounding variable candidates may be 
incorporated into predictive (statistical or causal) models.  
3.3.1 LBD-informed Statistical Modeling 
As there is no structure in statistical modeling, the integration of literature-derived 
covariates is simple. Once a set of covariates has been chosen, a model and a regression 
coefficient may be extracted for further processing.  
Domain knowledge extracted from the literature assists in the automated construction of 
statistical models in at least two ways:  
1. By identifying relevant covariates informed by semantic constraints, the input 





2. Given semantic constraints of the literature-derived confounders, this reduces the 
computational requirements when using a regularization method (ridge or lasso 
regression) to reduce the set of covariates.  
3.3.2 LBD-informed Causal Modeling 
Causal inference requires some means to automate the process of identifying contextually 
relevant covariates (feature selection) to scale. Domain knowledge extracted from the 
literature assists in the automated construction of causal models in three ways:  
1. By identifying relevant covariates informed by semantic constraints, the causal 
graphs are populated with nodes/covariates; 
2. Given semantic constraints of the literature-derived confounders, the edges of the 
graph can be oriented in the event of “data equivalence” of the learned graph 
structure.  
3.  Prior information concerning the orientation of graph edges helps 
computationally to reduce the search space for learning the graph structure. 
Once the structure has been learned, the relationship between nodes may be estimated. 
So, LBD can provide contextually relevant domain knowledge to facilitate the 
automation of causal modeling. This section will describe the methods that have been 
developed to facilitate predictive modeling in pharmacovigilance. 
Causal modeling for pharmacovigilance. Moving from these theoretical 
considerations, I will describe how sets of such confounders can be identified for 
inclusion into causal models for de-confounding observational clinical data derived from 





3.3.3 Methodological Overview and Evaluation Framework 
The next subsections describe the process of constructing a causal knowledge base using 
PSI and the steps for using this knowledge base to identify, validate, and include 
literature-derived covariates in statistical and causal models. 
3.3.3.1 Materials 
This subsection introduces the data that will be used in a series of experiments for 
evaluating the method. The data that one first receives are seldom in the shape that they 
need to be for practical use. The next section describes how the raw data were collected 
and processed into a representation amenable to downstream analysis. 
EHR data. Clinical text derived from electronic health records is the primary 
source of raw data for this dissertation. Data from structured fields were not included in 
the analysis, only unstructured text. Unstructured text data is known to contain valuable 
information that is not contained in structured data – this may include indications of 
“temporal relations, severity and degree modifiers, causal connections, clinical 
explanations, and rationale” (Johnson et al., 2008). The primary unit of analysis is the 
individual electronic health record which represents a single, unique visit by a patient to a 
clinician. EHR data was obtained after obtaining permission from the [UTHealth] 
Internal Review Board (IRB). A corpus of approximately 2.2 million electronic health 
records (EHR) was extracted from the UTHealth’s clinical data warehouse concerning 
outpatient encounters for ~ 364,000 patients in the Houston metropolitan area between 





system, was used to normalize concepts in the EHR corpus (C. Friedman, Shagina, 
Lussier, & Hripcsak, 2004). MedLEE has been shown to perform accurately on clinical 
notes, for example with a recall of 0.77, and precision of ~ 0.89 for the task of extracting 
clinical concepts (C. Friedman et al., 2004). In addition to identifying concept types 
("health outcomes of interest," "medications"), MedLEE also encodes each extracted 
concept with a concept unique identifier (CUI) from the Unified Medical Language 
System (UMLS) (A. R. Aronson, 2001; The Unified Medical Language System (UMLS)., 
2017).  
Next, for convenience, I indexed the MedLEE-process corpus of EHR data using Apache 
Lucene31 to facilitate the extraction of document-level co-occurrence statistics. From this 
index, document-by-concept arrays were obtained. A list of document ids specific to the 
Lucene index was extracted for each UMLS CUI in the index. Next, each concept (drug, 
adverse event, or adjustment set of confounders) was persisted as a large sparse binary 
array and compressed. In these binary arrays (input for causal algorithms), a value of 1 or 
0 represents presence or absence of that concept within a document in the corpus index. 
These arrays are later used as input for statistical and causal algorithms. These matrices 
can be constructed quickly, and can represent the observational data for each of the drugs, 
adverse events, and their confounders, and can provide input matrices for the causal 
methods to be described.  
                                               





Reference Dataset. Reference data sets are used for methodological evaluation in 
pharmacovigilance. These datasets customarily consist of a number of 
medication/adverse event pairs wherein there are cases (a causal relationship between 
exposure and adverse event has been established) and controls (no known relationship). 
A reference set of curated drug/adverse event associations that was developed by Ryan 
and his colleagues as a standard for evaluating pharmacovigilance method was used for 
methodological evaluation (Ryan, Schuemie, et al., 2013). This reference set includes 399 
drug/adverse event pairs for four clinically important adverse events with both positive 
(drug/adverse event relationships supported by the literature and other sources, including 
package labeling events) and negative (drug/adverse event relationships without support) 
control groups per adverse event. The four adverse events are as follows: acute kidney 
injury (AKI), acute liver injury (ALI), gastrointestinal bleeding (GIB), and acute 
myocardial infarction (MI). These adverse events were chosen for their importance to 
pharmacovigilance and for their impact on financial and personal cost. I mapped and 
expanded drug/adverse event synonyms to make the EHR data amenable to additional 
processing. I used RxNorm for drug synonyms at the clinical drug level, and I assigned 
the reference set’s Observational Medical Outcomes Partnership (OMOP)adverse event 
to UMLS CUIs (Nelson, Zeng, Kilbourne, Powell, & Moore, 2011; Observational 
Medical Outcomes Partnership (OMOP), 2017; RxNorm., 2017). For example, the 
generic concept “Ibuprofen” is encoded with a CUI string of “C0020740,” while the 





“C0305170.” To gain statistical power, these CUIs are reconciled into a single 
representation. Table 1 presents an overview of the reference dataset: 
Table 1 
Ryan et al. (2013) Reference Dataset 
Adverse Events  Case Control Total 
AKI (Acute Kidney 
Injury) 
24 64 88 
ALI (Acute Liver 
Injury) 
81 37 118 
AMI (Acute 
Myocardial Infarction) 
36 66 102 
GIB (Gastrointestinal 
Bleeding)  
24 67 91 
Total 164 164 399 
Note. Categories in far left denote health outcomes of interest phenotypes in the OMOP 
reference data set.  









3.3.3 Confounding Variable Discovery Process  
To construct a knowledge base for the present experiment, Predication-based Semantic 
Indexing was supplied to SemMedDB, a knowledge repository developed by the National 
Library of Medicine using SemRep (Cohen et al., 2009; Kilicoglu, Shin, Fiszman, 
Rosemblat, & Rindflesch, 2012; SemMedDB, 2017). PSI uses random projections and 
reversible vector transformations to derive distributed concept vector representations 
from SemMedDB, mediating efficient but approximate search, retrieval, and inference. 
The higher the dimensionality that is used, the better the recall and precision of the model 
(with a trade-off of computational efficiency). When searching for the missing argument 
of a predicate-argument pair, concepts that fill this role most frequently will be retrieved 
first, analogous to the ranking of results in search engines. In the current work, PSI is 
used to facilitate rapid retrieval and rank ordering of concepts related to other concepts 
through particular predicates.  
3.3.3.1 Querying PSI Spaces with Discovery Patterns to Identify Potential 
Confounders 
The Semantic Vectors package (Semantic Vectors, n.d.) provides an interface that 
permits searching PSI spaces for concepts that populate particular predicate discovery 
patterns, which I used to identify the most strongly associated confounders for each 
drug/adverse event pair. If the following discovery pattern is used to identify 
confounding variable candidates: “drug TREATS confounder; confounder CAUSES-





infarction as cue terms, “metabolic disorder” will be obtained as one of the results. The 
order in which these covariates are retrieved reflects their ranked relevance given the 
distributional semantics of the query terms in the index. Sample confounders for 
abacavir, an antiretroviral used to treat AIDS in the negative control group for 
gastrointestinal bleeding, include (by ranked order of relevance): Dieulafoy’s vascular 
malformation, HIV infections, lipoatrophy, HIV encephalopathy, and angiodysplasia. 
Further down the list, confounders become less specific: peptic ulcers and diabetes. In the 
evaluation, I excluded spurious associations (as all vectors in the space are a measurable 
distance apart) from confounders, making use of a frequency threshold, such that only 
bridging terms with association strengths 2.5 standard deviations were included. More 

























drug:                   allopurinol 
adverse event:    liver 
failure 
X CAUSES adverse_event co-medication, 
comorbidity 
transplantation, embolism 
X PREDISPOSES adverse_event co-medication, 
comorbidity 
transplantation, embolism 
drug TREATS X; 
X COEXISTS_WITH adverse_event comorbidity 
pericarditis, gout, kidney 
failure  
 
drug TREATS X; 
X CAUSES adverse_event 
comorbidity hyperuricemia, gout 
 
Note. Items are in far left and denote the discovery patterns used in the experiments. The 
first three discovery patterns were used only in the first experiment (Chapter 5), whereas 
the fourth discovery pattern was used in Chapter 5 (“graph structure”) and Chapter 6 
(“using simulations to quantify average treatment/causal estimates”). 
 
A browser interface called EpiphaNet has been developed for querying PSI-based 
representation of SemMedDB using a query language with metavariables that specify 
predicate vectors, elemental vectors, semantic vectors along with binding and 
                                               
32 In previous research in causal modeling, Cheng refers to such covariates as “focal sets” (Cheng, n.d.). 
Greenland et al. refer to confounding variable candidates as “potential confounders” (S. Greenland et al., 
1999). Pearl et al. refer to the “focal set” of “potential confounders” as the “causal story” (J. Pearl, 





superposition operators (Cohen et al., 2009; Cohen, Schvaneveldt, et al., 2010; Cohen, 
Whitfield, et al., 2010; Cohen et al., n.d.; Kanerva et al., 2000; Widdows & Cohen, 
2015). PSI vector space model of SemMedDB may be queried to identify confounding 
variable candidates for each drug/adverse event pair with PSI queries that represent 
discovery patterns. The results of a query through EpiphaNet’s 
(http://www.epiphanet.uth.tmc.edu) web interface are shown below in Figure 2:  
 
Figure 2. Illustration of EpiphaNet query results. EpiphaNet query results for 
rosiglitazone and myocardial infarction are depicted. Note that the direction of the arrows 
for TREATS reflects the semantics of that predicate. In causal terms, the edge is oriented 








3.3.3.2 Individual validation of confounder candidates with EHR data 
When applying machine learning algorithms, it is vital to perform feature selection as it 
will reduce the number of variables that are used to construct the model (current 
reference). Having variables that are irrelevant can hinder analysis by increasing the 
processing time, reducing available resources, and often lowering the accuracy and 
precision of models through the introduction of multicollinear covariates. The implication 
of this is that in either statistical or causal models, each literature-derived confounder 
must meet a series of constraints for inclusion into downstream predictive models. The 
first constraint entails first determining that it has been measured in the EHR data, as this 
is a prerequisite to both further validation and predictive modeling. Secondly, each 
confounding variable candidate must be correlated with at least the outcome (Chapter 4 – 
initial experiments), if not both the predictor and the outcome (Chapter 5 and Chapter 6). 
Validation entails first determining that it has been measured in the EHR data. Secondly, 
each confounding variable candidate must be correlated with at least the outcome 
(Chapter 4), if not both the predictor and the outcome (Chapters 5 and Chapter 6). The 
justification for excluding variables that are not correlated with both predictor and 
outcome is that such covariates fail to meet the criteria as confounders and so to be of  
potential use in de-confounding observational data.  
3.4 Summary and Roadmap for following chapters 
In this chapter, I have sketched an outline of the framework that I have developed for 





causal models. I will further develop and refine these ideas given the course of iterations 
and refinements in the chapters that follow. Additional details concerning the data and/or 
methods are specified in those respective sections of the forthcoming chapters. The items 
enumerated below provide an outline of the general steps that hold across the 
experiments to be described in detail in the forthcoming chapters.  
1. Extract, process, and persist observational clinical data from the clinical data 
warehouse (after obtaining approval from the [UTHealth] IRB. 
2. Construct knowledge base of domain knowledge extracted from the literature. 
3. Apply or research relevant synonym mappings for medications and adverse events 
from a publicly available reference dataset to be used for methodological evaluation. 
4. Evaluate baseline performance of EHR data for pharmacovigilance signal detection 
using desired method (odds ratio, logistic regression) without confounding adjustment 
by calculating the area under the curve of the receiver operator characteristic curve 
using baseline scores for each drug/adverse event pair in the respective reference 
dataset. 
5. Query the knowledge base for contextually relevant confounders using each 
drug/adverse event in the reference dataset as cue terms, given a discovery pattern, 
and determine if the literature-derived covariate behaves like a “confounder.” 





7. Evaluate confounder adjusted performance of EHR data for pharmacovigilance 
signal detection using desired method (odds ratio, logistic regression) without 
confounding adjustment by calculating the area under the curve of the receiver 
operator characteristic curve using adjusted scores (parameter metrics, regression 
coefficients) for each drug/adverse event pair in the reference dataset.  
If the pre-processing procedures may be abstracted out, since these have been completed 
by the time individual experiments begin, the steps above may be reduced to those 
illustrated in Figure 3 below: 
Figure 3. Illustration of LBD-informed causal modeling framework. This illustration 
represents the study design of the method and experiments. Each experiment can be 
thought of a “variation on a theme”: the particular elements may vary (reference data set, 
the provenance of clinical data, modeling class [statistical or causal] or algorithm), but 







Variations on Figure 3 will be revisited and adapted for the experiments presented in the 
chapters that follow. Individual elements concerning implementation details will vary 
(statistical vs. causal modeling, discovery pattern), but the overall workflow will be 
consistent. 
Roadmap for the forthcoming chapters. Chapter 4 describes an experiment 
wherein I integrated literature-derived confounders into statistical models using step-
forward logistic regression and three “discovery patterns”. Chapter 5 presents an 
experiment where I used combinatorial permutation upon sets of literature-derived 
confounders as a scoring mechanism using a discovery pattern that identifies co-
morbidity-type confounders with a “drug TREATS x; x CAUSES adverse_event” dual 
predicate discovery pattern. Chapter 6 describes and evaluates a method to obtain 
estimates of the average treatment effect of the likelihood of medications to cause 
adverse events, using the same discovery pattern from Chapter 5. Finally, Chapter 7 
presents the accomplishments, contributions, limitations, and possible directions for 






Chapter 4: Using the Literature to De-confound Statistical Models 
The material in this chapter was presented at AMIA Symposium 2016, Chicago, IL: 
Malec, S. A., Wei, P., Xu, H., Bernstam, E. V., Myneni, S., & Cohen, T. (2016).  
Literature-Based Discovery of Confounding in Observational Clinical 
Data. AMIA Annual Symposium Proceedings, 2016, 1920–1929.  
This chapter constitutes the initial exploratory analysis of LBD-informed 
predictive modeling. As can be expected from an exploratory analysis, the 
methods and concomitant results presented are as yet in their infancy. LBD 
techniques are used to cast a wide net to identify intervening variables. Initially, 
any sort of intervening variable will do (confounder, mediators, alternate 
etiologies33). These intervening variables must meet at least two criteria in order 
to be considered for inclusion in statistical models: 1.) they must be 
mechanistically related to at least the health outcome (adverse event) in the 
literature through pre-defined relationships (“discovery patterns”); and 2.) they 
must be correlated with both (predictor and outcome) in the EHR data. The 
objective of this study was to see which discovery pattern or type of intervening 
variable would work the best (or at all) for improving the quality of 
pharmacovigilance signals in EHR data. Critical lessons were learned and 
                                               
33 The broadness of this initial motivation does not fit with the exclusive focus on confounders, but at the 
conclusion establishes this focus, preparing the way for the next two chapters/experiments, where the focus 





ideas evolved quickly from this initial conception, as shall be seen in the next 
two chapters.  
4.1 Introduction  
The hypothesis evaluated in this chapter is that statistical models, adjusted with 
literature-derived covariates, will more accurately identify causative drug/adverse event 
relationships than baseline unadjusted models. In this experiment, intervening variable 
candidates (hereon to be referred to as confounding variable candidates, or confounding 
variable candidates) from three discovery patterns are integrated into statistical models 
using forward stepwise logistic regression, and their capacity to de-confound 
drug/adverse event signal in EHR data (from the UTHealth clinical data repository 
(UTHealth BIG., 2017)) is evaluated using the OMOP reference dataset for 
pharmacovigilance (Ryan, Schuemie, et al., 2013). EHR data and the reference dataset 
were pre-processed as described in section 3.3.2 of the previous chapter.  
Definitions. A confounding variable influences or biases the magnitude of the 
correlation between a predictor variable (e.g., drug exposure/treatment) and a response 
variable (i.e., outcome/adverse event). In the context of creating models for 
pharmacovigilance, when a confounding relationship exists between a falsely associated 
drug/adverse event pair and adjustments are made to account for its influence, the 
association strength for that relationship should be diminished. For example, given a set 
of observational clinical notes, it is observed that fish oil intake is highly correlated with 
acute liver injury (ALI). However, after adjusting the model for the presence of known 





should approach zero. Let us consider another example of an acetaminophen exposure 
(predictor) and a hepatitis B infection (predictor) where the patient subsequently suffers 
ALI (response). In this case, each of these predictors, independently, are sufficient 
preconditions for ALI. As they occur together, these two predictors may confound each 
other. When the association of either predictor is adjusted in the absence of the other 
predictor, the association may diminish, but not as dramatically as in the first example. Li 
et al. introduced a taxonomy of confounding in pharmacovigilance with the following 
categories: confounding by indication (e.g., preexisting conditions), confounding by 
comorbidity (e.g., diabetes), and confounding by co-medication (e.g., aspirin) (Y. Li et 
al., 2014; Talbot & Aronson, 2012).  
A mediating variable, by contrast, lies distinctly along the causal discovery 
pattern between the predictor variable and the response variable themselves and may be 
neither necessary nor sufficient to cause an adverse event by itself. Mediators may 
sometimes be thought of as “risk factors” or as aspects of the etiology of the adverse 
event itself (Richiardi, Bellocco, & Zugna, 2013; Valente, Pelham, Smyth, & 
MacKinnon, 2017). Examples of mediators include bile duct obstruction for (acute liver 
injury/failure) ALI or hypertension for myocardial infarction (MI). For a more detailed 
discussion of mediation, see (Judea Pearl, 2009; Richiardi et al., 2013; Tchetgen 







4.2 Materials and Methods 
Knowledge Base. A PSI vector space derived from version 24_32 of SemMedDB 
(processed with version 1.5 of SemRep), containing 23.9 million citations and 70.4 
million semantic predications (SemMedDB, n.d.) was used to construct a knowledge base. 
A knowledge base consists of assertions of an etiological nature derived from the 
literature. In this case, this knowledge base will be used to identify sets of covariates that 
may be pertinent to an evaluation of putative drug/adverse event relationships of interest. 
A 48,000-dimensional binary vector PSI space was built using the Semantic Vectors 
package (version 5.9) (Semantic Vectors, n.d.). Predicates were excluded that indicate 
negation (e.g., DOES_NOT_TREAT), as well as terms (“stop words”) with occurrence 
≥	500,000.  
Derivation of confounding variable candidates from the literature. The 
discovery patterns used in this chapter’s experiment are presented and summarized in 
Table 3 below. These discovery patterns were identified while studying how domain 
experts used of the EpiphaNet LBD interface to interpret results of drug/adverse event 
queries. EpiphaNet would at times generate reasoning discovery patterns that suggest 
confounding relationships. Note that “drug TREATS x; x COEXISTS_WITH 
adverse_event” is referred to as a “double predicate” discovery pattern in that it is 
composed of two predicates that yield confounding variable candidates that link to both 








Discovery Patterns (“DPs”) for Statistical Modeling 
DPs  Confounding Type 
Examples 
drug:                 allopurinol 
adverse event:  liver 
failure 
X CAUSES adverse_event co-medication, 
comorbidity 
transplantation, embolism 
X PREDISPOSES adverse_event co-medication, 
comorbidity 
transplantation, embolism 
drug TREATS X; 
X COEXISTS_WITH adverse_event comorbidity 
pericarditis, gout, kidney 
failure  
 
Note. Categories in far left in bold denote the discovery patterns used in this experiment.  
 
Methods  
Preprocessing steps for the data and knowledge base were described previously in 
Chapter 3. Note that the input consists of document level concept occurrence statistics for 
drugs, adverse events, and literature-derived covariates for statistical models.  
Establish baseline performance by calculating the area under the curve from the 
receiver operator characteristic34 (AUROC) curves from ranked-order of coefficients 
from unadjusted logistic regression models.  
                                               
34 AUROC is a popular metric used to summarize the performance of binary classifiers in statistical 






1. Query PSI vector space for confounding variable candidates given each 
drug/adverse event pair for confounding variable candidates and extract data from 
the index. Fifty confounding variable candidates were extracted for each pattern 
per drug/adverse event pair. The constraint for the inclusion of a confounding 
variable candidate into a statistical model is at least ten co-occurrences given the 
EHR data for both the drug and the adverse event. 
2. Construct confounding variable candidate-adjusted statistical models using 
forward stepwise logistic regression and calculate the aggregated performance 
statistics with AUROC. The statistical models are constructed in descending order 
of co-occurrence count between drug, adverse event, and confounding variable 
candidate concepts (with an intersection threshold of ten) for inclusion in the 
statistical models. AUROC is calculated using the ground truth in the OMOP 
reference data set (Ryan, Schuemie, et al., 2013) and the ranked ordering of the 
regression coefficients from the generalized linear models of the drug/adverse 
event pairs. 
In the course of building models iteratively in step 3 above, when the statistical 
model achieve a fit with a newly incorporated literature-derived covariate, that covariate  
is incorporated into subsequent models. Confounding variable candidates that are 
collinear with the exposure/drug and the adverse event may result in models that fail to 
converge, or achieve a fit. This process continues for each drug/adverse event pair until 
confounding variable candidates are exhausted for that discovery pattern. When such 





for that pair so that it will not be included in subsequent builds, and it is retained for 
manual investigation for interesting patterns. If none of the models for a drug/adverse 
event pair converge using confounding variable candidates, then the score from the 
unadjusted, or baseline, logistic regression coefficient is used to calculate AUROC. The 
data analysis methods used in the current experiment are as follows both in the text and in 
Figure 4 below:  
 
Figure 4. Illustration of LBD framework for statistical modeling. EHR data derived from 
the UTHealth clinical data warehouse was used as primary input and to test the literature-
derived covariates. Literature-derived confounders from three discovery patterns will be 
included in statistical models of EHR data using forward stepwise logistic regression: 








4.3 Results  
Table 4 
Results for LBD-informed Statistical Modeling   
 
Complete Results Constrained Results 
AEs  DPs Counts +/- Baseline Adjusted Counts +/- Baseline Adjusted 
AKI  Caus   
0.5547 
0.5853 11/13 0.6573 0.6643 
 Pred 24 / 64 0.584 NA NA NA 
 Tcoe  0.6126 NA 0.6972 0.6125 
ALI  Caus   0.515 44/14 0.5536 0.5568 
 Pred 81/37 0.4957 0.5297 50/24 0.4992 0.4825 
 Tcoe   0.492 58/25 0.509 0.5303 
AMI  Caus   0.5158 24/41 0.6026 0.6148 
 Pred 36/66 0.5112 0.5196 30/47 0.5319 0.5574 
 Tcoe   0.5032 27/45 0.5687 0.5835 
GIB  Caus   0.6418 20/48 0.6073 0.5792 
 Pred 24/67 0.5643 0.699 20/49 0.5949 0.6571 
 Tcoe   0.7189 20/50 0.5964 0.69 
Note. Categories in far left denote adverse events adverse events (AE) in the OMOP 
reference data set. The next column denote discovery patterns. This table presents the 
baseline and adjusted AUROCs that were calculated from the ranked order of logistic 
regression models from each adverse event and discovery pattern combination. Caus = ”x 
CAUSES AE,”  Pred = ”x PREDISPOSES AE,” Tcoe = ”drug TREATS x; x 
COEXISTS_WITH AE.” Counts = number of positive/negative examples. AUROCs in 





There are two groupings of result data in Table 4, labeled Complete Results and 
Constrained Results. Complete Results indicates that the AUROCs have been calculated 
from the full data set without imposing any additional criteria.  
In the Constrained Results, the following criteria were applied to calculate 
performance metrics values for each field per adverse event/discovery pattern row such 
that:  
1.) All logistic regression models must have converged35.  
2.) The count for drug instances was ≥ 100 in the EHR data.  
3.) The count for intersections was ≥ 10 between drug/adverse event pair.  
4.) The calculations derive exclusively from cases where confounding variable 
candidates were included in the logistic regression models.  
As a result, the count of positive and negative controls for the same adverse event will 
vary, since confounding variable candidates differ between discovery patterns.  
Observations. There were ~55,000 instances in the EHR index for each of ALI, 
AMI, and GIB. AKI was the outlier with only ~5,000 instances. In the case of AKI for 
the “x PREDISPOSES adverse_event” discovery pattern, no co-occurring confounding 
variable candidates were identified so that no adjustment could be made. In the case of 
ALI, one might reason that the set is heavily weighted toward the positive examples, so 
little gain is to be had by adjusting with confounding variable candidates.  
                                               
35 Some covariates are colinear with predictor, outcome, or both causing perfect or quasi-perfect 







Analysis of Constrained Results. In the Constrained Results, for models that 
include confounding variable candidate adjustments, performance improved in 8 of 
eleven cases. The “drug TREATS x; x COEXISTS_WITH adverse_event” discovery 
pattern improved performance in three or four cases, while the same can be said in two of 
four “x PREDISPOSES adverse_event.” In only one case, AKI there was an 
improvement using the “x CAUSES adverse_event” discovery pattern36.  
 Li et al. recently developed a data-driven confounding variable discovery method 
using a propensity score method (PSM) (Jackson et al., 2017; Rosenbaum & Rubin, 
Donald, 1983; Tatonetti et al., 2012) to identify factors associated with the treatment and 
another technique to identify factors associated with the outcomes (R. Harpaz et al., 
2012) – in this case, rhabdomyolysis and pancreatitis. Overlaps between these two sets 
(of the “comorbidity” subtype in pharmacovigilance) were collected and processed using 
penalized regularization methods, specifically lasso regression (Y. Li et al., 2014). The 
results are not strictly comparable with this study as the input data and drug/adverse event 
pairs are different, but the best improvement was with the method above compared with 
only the PSM or risk factor scores, and when there were a sufficient number of 
exposures: at least 100. In another study in purely EHR-based pharmacovigilance, Li 
                                               
36 The “x CAUSES adverse_event” discovery pattern is an intriguing start, however. It will be re-deployed 






combined FAERS with EHR data to obtain a 0.22 improvement in AUROC – from 0.51 
to 0.73 (Y. Li, 2015).  
 Error Analysis. While it makes sense to use the single predicate 
discovery patterns that imply causation or risk factors, e.g., “x CAUSES adverse_event,” 
“x PREDISPOSES adverse_event,” respectively, concerning their ostensible causal 
association for adjusting negative controls, the results of my analysis did not support this 
intuition. Such discovery patterns uncover concepts that exist in the gray area between 
mediators, risk factors (Pearl’s “indirect effects” predictors), and concepts which could 
manifest confounding effects, e.g., smoking with respect to a positive control drug and 
AMI (Judea Pearl, 2009). For example, the following cases of mediator­like confounding 
variable candidates from this discovery pattern were identified: stenosis, obstruction, 
thrombosis, and thrombus. Such concepts are suggestive of mediating concepts that relate 
to the causal mechanisms for AMI. Since mediators tend to be collinear with response 
variables, inclusion of such confounding variable candidates may be detrimental to 
performance (although means to correct for bias from such variables have been 
developed and have been explored at length elsewhere) (Aalen, Roysland, Gran, & 
Ledergerber, 2012; Richiardi et al., 2013; T. J. VanderWeele, 2012; Vanderweele, 
Vansteelandt, & Robins, 2014).  
Wordclouds. I have generated word clouds below in Figure 5. The purpose of 
these wordclouds is to present examples of the types of concepts that were identified by 
LBD. The wordclouds were generated using R’s wordcloud library (Fellows, 2014). The 





wordcloud indicates the prevalence of the concept. The first two wordclouds represent 
the confounding variable candidates of ALI, and GIB with the “x CAUSES 
adverse_event” discovery pattern. The third and fourth show the confounding variable 
candidates for the AMI groups using the “x CAUSES adverse_event” discovery pattern. 
The fifth word cloud represents the confounding variable candidates that were excluded 
when building the logistic models for GIB using “drug TREATS x; x 
COEXISTS_WITH adverse_event” discovery pattern. These literature-derived 
confounding variable candidates were identified in the literature, but failed to meet the 
inclusion criteria in the EHR data. The reader will notice that confounding variable 
candidates from single predicate discovery patterns (e.g., “x CAUSES adverse_event”) 
that were associated only with the adverse event were of both the comorbidity and co-
medication confounding subtypes, whereas confounding variable candidates from “drug 
TREATS x; x COEXISTS_WITH adverse_event” are constituted exclusively by 
comorbidities. The fourth word cloud (bottom row, left) is interesting in that the most 
prevalent confounding variable candidates are comorbidities and likely mediators of 







Figure 5. Illustration of Wordclouds from statistical modeling discovery patterns. 
These word clouds represent confounding variable candidates for adverse events and 
discovery patterns with font size proportional to aggregated term frequency (across all 
drugs for a group [positive or negative control] of a given an adverse event and a 





One perplexing confounding variable candidate from “drug TREATS x; x 
COEXISTS_WITH adverse_event” discovery pattern for acute myocardial infarction is 
fibroid tumor. Fibroid tumors of the gastrointestinal tract are relatively rare and usually 
appear on the uterus. However, review of the predication database suggested that at times 
anti-inflammatory agents may occur in TREATS relationships with fibroid tumors, as 
they are used to control the pain associated with this condition. Though the “drug 
TREATS x; x COEXISTS_WITH adverse_event” discovery pattern is intended to 
retrieve terms that are associated with both the drug and the adverse event, the underlying 
implementation involves vector superposition. Although I would anticipate terms that are 
bilaterally connected being retrieved first, terms that are unilaterally connected may still 
meet the threshold. Such spurious confounding variable candidates could be eliminated 
by using a higher threshold of associational strength than the 2.5 standard deviation level 
and by making a bilateral connection a prerequisite for retrieval37.  
Conclusion. With the aim of surmounting the obstacle of confounding, a 
phenomenon which diminishes the validity of information that can be extracted from 
observational data, I have proposed a scalable and computationally inexpensive LBD-
based confounding variable discovery method. The evaluation shows that when there is 
sufficient support above random for an adverse event, i.e., AUROC 0.6, statistical models 
                                               
37 Recall that there is a multi-stage filtration of confounding variable candidates. First the confounding 
variable candidates must meet the distributional requirements in the PSI space. In vector space everything 
is connected, so concepts that are retrieved must score above 2.5 standard deviations as noted to be 
retrieved. Secondly, the confounding variable candidate that is identified with a score above the 
distributional threshold must meet additional requirements: they must be measured/recorded and those 
values must overlap at minimum ten times with both the predictor and outcome variables. Finally, 
confounding variable candidates cannot be colinear with the predictor and outcome variables as this will 





that incorporate adjustments for the influence of dual-predicate discovery pattern-derived 
confounding variable candidates exhibit modest (0.05 AUROC or higher) performance 
gains for the task of re-identifying drug/adverse event pairs from observational clinical 
data.  
This study had several limitations. These include: 
1.) The discovery patterns that were used may not have identified “true” 
confounders or mutual causes, but “alternate etiologies” and “mediators.” 
a. An “alternate etiology” is another causal explanation for why 
something occurred, and it may be independent of the explanatory 
variable. It may not be useful for disentangling spurious associations 
due to statistical correlation.  
b. Like confounders, mediators are another type of intervening variable 
between a predictor variable p and an outcome of interest o. However, 
whereas a confounder C will betray this pattern: p Ü C Þ o, a 
mediator M will have this pattern: p Þ M Þ o. 
2.) The best performing discovery pattern was a dual predicate discovery pattern. 
While the TREATS predicate offers strong evidence from the literature that 
the co-morbidity bridging term may be responsible for causing or increasing 
the likelihood of the exposure, the COEXISTS_WITH predicate does not 
provide a strong indication that its object is viable mechanistically, but it is 





confounders, they do offer clues as to how strong confounding variable 
candidates might be identified.  
The main lesson learned from this study is that dual predicate discovery 
patterns are powerful tools for identifying useful confounding variable 
candidates. In thinking about how the two types of intervening variables 
relate to each other (mediator and confounder), confounders of the mutual 
cause type were more easily understood and they performed better in the 
aggregate. This indicated the direction to proceed.  
The next two studies expand upon the LBD component of this initial 
analysis and explore a more precise definition of confounder that was only 
hinted at in this chapter. However, mediators will make a return (albeit in 
refined form) in the discussion of future research in the final chapter, as 
mediators turn out to be vital components of future directions of research in 
LBD-informed modeling of EHR data. 
The research that follows attempts to transcend associational methods. In 
the next chapter, an experiment is presented that explores ways in which 
asymmetric direction of influence inherent in causal predications can be 






Chapter 5: Ars Combinatoria with Focal Sets of Potential Confounders 
The material in this chapter was presented at the DMMI Workshop, part of the AMIA 
Symposium 2017 held in Washington D.C.: 
Malec, S., Gottlieb, A., Bernstam, E., & Cohen, T. (2018). Using the Literature to 
Construct Causal Models for Pharmacovigilance. https://doi.org/10.29007/3rfr 
 
In the previous chapter, the interpretation of an intervening variable was left 
quite open: it could either be a mediator or a confounder. Moving from “mere 
association” of logistic regression models, the experiment described below 
explores intervening variables more precisely. Specifically, the thought behind 
what the definition is and individual confounders behave or can be expected to 
behave collectively and individually become more precise and nuanced. This 
chapter introduces a new method to validate confounding variable candidates 
using the directionality inherent in the semantic predications, since graph 
structures with instantiated nodes, i.e., populated with values from the EHR 








5.1 Introduction  
There can be said to be two distinct but related types of information encoded in 
causal graphs: qualitative38 and quantitative. The qualitative aspect is more apparent: this 
may be readily ascertained by the presence or absence of directed edges, characterized as 
pointing in one or in the opposite direction. If a causal edge is present, influence will flow 
in the direction in which that edge is pointing and produce and increase (or prevent and 
decrease) the likelihood of the entity that is on the other side to occur. The other aspect is 
quantitative – this is the problem of estimating the magnitude of the strength of that edge, 
i.e., the “structural coefficient.”  
In the experiment described in this chapter, the focus is on the qualitative 
detection of edges in the graph topology learned by causal discovery algorithms and 
imputed by causal propositions (predications) mapped from the literature. The operative 
hypothesis is that the presence of sets of literature-derived confounding variables (hereon 
to be referred to as “focal sets” of confounding variable candidates after Cheng (Cheng, 
n.d.; Cheng & Novick, 1990)) will diminish the detection of spurious drug/adverse event 
dependencies as encoded in graph structure in the aggregate. 
However, since an AUROC cannot be calculated with binary values (the 
qualitative aspect of graphs mean that an edge is either absent or present), a means to 
                                               
38 Qualities are conceived as discrete, binary-valued: one either possesses an attribute or one does not, 
whereas one thinks of quantitative values as being continuous. At the stage of causal modeling that this 
experiment was drawn from, estimating the strength of influence between variables in causal models was 
not yet technically feasible. The experiment presented here is the result of a compromise between what I 





derive continuous values was devised by using the literature and EHR to identify a focal 
set and using all unique combinations of that set as input to causal discovery algorithms. 
By dividing the number of resulting causal edges detected by the number of 
permutations, a metric with a continuous value was attained with which to calculate the 
aggregate performance of the causal discovery algorithm using AUROC. AUROC 
provides a means to weigh sensitivity (or recall: the ability to identify True Positives) 
against specificity, the capacity of a classifier to guard against the identification of 
spurious signals as positive. The evaluation metrics and procedure will be discussed in 
greater detail below. 
5.2 Materials and Methods 
Data Sources. To evaluate this hypothesis, the same pre-processed EHR data and 
reference dataset were used as in Chapter 4 (Ryan, Schuemie, et al., 2013; UTHealth 
BIG., 2017).  
Discovery Pattern for Confounding Variable Discovery. Semantic Vectors 
provides an interface that permits searching PSI spaces for concepts that populate 
particular predicate discovery patterns, which I used to identify the most strongly 
associated confounding variable candidates for each drug/adverse event pair. I used the 
following discovery pattern to identify possible confounding variable candidates: “drug 
TREATS confounder; confounder CAUSES adverse_event.” For example, given 
rosiglitazone and gastrointestinal bleeding, “diabetes mellitus, non-insulin-dependent” 





type “true”/”proper” confounders39; that is, mutual causes that increase the co-occurrence 
of both the explanatory and the outcome variables (Judea Pearl, 2009). 
TETRAD and FGeS. TETRAD is an open source causal modeling and discovery 
toolkit written in Java that has been in continuous development at Carnegie Mellon 
University since the early 90s (Scheines et al., 1998). Depending on one’s choice of 
algorithm, the input may be discrete, continuous, or mixed. The discrete version of the 
Fast Greedy Equivalence Search (FGeS) included with TETRAD with default parameters 
(Ogarrio et al., 2016) was used to infer graph structures from the EHR data.  
FGeS recursively adds and then subtracts directed edges between nodes until the 
Bayesian Information Criterion40 (BIC) is minimized. The output consists of a family of 
score-equivalent graphs which encode plausible dependency relationships given these 
data such that the orientation of the directed edges could not be determined from the data 
alone, i.e., graphs encoded by this structure have the same BIC score (Heckerman et al., 
1995, 1995). However, background knowledge can be used to orient these edges, as 
causal predicates have inherent directionality. The resulting graph structure of a 
literature-derived confounding variable candidate should have a graph within this 
equivalence class with directed edges to both the drug and the adverse event 
(“confounder inclusion criterion”).  
                                               
39 Proper confounder as per the Greenland et al. definition (S. Greenland et al., 1999; Weinberg, 1992). 
40 For continuous Gaussian data: 𝐁𝐈𝐂 = 	𝐧	 𝐥𝐧(𝛔	̂𝐞𝟐) + 𝐤	𝐥𝐧	(𝐋	̂) where 𝑳	̂ = the argmax of the likelihood 





Combinatory Expansion of Confounding Variable Candidates. If I have a set 
of three confounding variable candidates, denoted {A, B, C}, this will result in seven 
unique combinations of focal sets: A, B, C, AB, BC, AC, and ABC (AB and BA are 
equivalents). At five confounding variable candidates per focal set, there are thirty-one 
unique combinations. I evaluated these because it is not known which combination of 
confounding variable candidates, if any, would cause spurious drug/adverse event graph 
dependencies to vanish.  
Analysis of Observational Clinical Data. The steps were as follows:  
1. Confounding variable candidate identification. Query PSI vector space for 
confounding variable candidates given each drug/adverse event pair for 
confounding variable candidates and extracted EHR data.  
2. Confounding variable candidate validation. Use TETRAD/FGeS to construct 
and validate confounding variable candidates individually in ranked order of their 
relatedness to the PSI query, by testing each individually for directed edges to the 
drug/adverse event pair, and halting when five of the top-ranked confounding 
variable candidates for each drug/adverse event pair had been validated. 
3. Confounding variable candidate permutation. Use combinatorial expansion to 
permute all combinations of confounders. 
4. Causal discovery. For each of the confounding variable candidate permutations, 
use TETRAD/FGeS to determine whether or not a causal edge from predictor 






5. Aggregation. Calculate the proportion of confounding variable candidate 
permutations for which a causal edge is present, and evaluate aggregate 
performance using AUROC from the ranked order drug/adverse event pairs per 
this proportion (such that those pairs with the highest proportion of causal edges 
across permutations will be most highly ranked). 
Evaluation Procedure. To calculate and compare performance, I calculated the 
Area Under the Curve of the Receiver Operating Characteristic curve (AUROC), which 
is widely used to evaluate the performance of classifiers against a ground truth of positive 
and negative controls, based on the ranked order of a continuous estimate of the strength 
of predicated relationships. AUROC treats both Types I (“false negative”) and Type II 
(“false positive”) errors symmetrically. For baseline scores, I used correlation coefficients 
from logistic regression models without the incorporation of literature-derived 
confounding variables.  
Evaluation Metrics. Causal model scores are calculated from the number of 
directed edges from the drug to the adverse event divided by the total number of 
permutations. The hypothesis is that the proportion of directed edges of positive cases in 
the reference dataset from the drug to their respective adverse events will be higher for 
the group of positive control drug/adverse event pairs than for the negative pairs in the 
reference dataset. In other words, the current study tests whether the associations from 
co-occurrence in the clinical data of a drug/adverse event pair are diminished conditional 
on sets of other concepts (i.e., validated confounding variable candidate permutations). 










Results from Focal Set Permutation Experiment 
Adverse events  Total Baseline Causal Models 
AKI (Acute Kidney 
Injury) 
24/64 0.5547 0.6598 
ALI (Acute Liver 
Injury) 
81/37 0.4957 0.5449 
AMI (Acute 
Myocardial Infarction) 
35/64 0.4946 0.56 
GIB (Gastrointestinal 
Bleeding)  
24/67 0.5643 0.6912 
Total 164/232 0.504 0.5813 
Note. This table presents the AUROCs as calculated from the aggregated logistic 
regression coefficients (Baseline) and the fraction of directed edges from the causal 
graphs. Pairs = number of test/control drug/adverse events from the Ryan reference 
dataset. AUROCs in bold indicate that the causal models outperformed the baseline 






Analysis of Results. 1915 out of 2124 total tested confounding variable 
candidates (for 399 drug/adverse event pairs each with five confounders) were both 
present in the clinical notes and passed validation, so the confounding variable candidate 
yield rate was 90%, indicating that LBD can identify confounders in clinical notes. As 
shown in Table 5, the overall aggregate performance boost that approached ~ 0.08 over 
statistical models confirms our hypothesis that the identification problem of confounding 
can be partially resolved by using the literature to inform feature selection41 (an area that 
I have addressed earlier with using LBD for statistical models) (Malec et al., 2016). The 
method performed the best when the baseline AUROC for drug safety signal was 
sufficiently above the level of noise (~ 0.5 AUROC). GIB, followed by AKI, had the best 
baseline AUROC. By contrast, MI and ALI hardly budged from noise to signal, 
indicating that the method requires a reliable initial baseline to be effective.  
Practical Significance. Better detection methods in pharmacovigilance, if 
implemented, hold promise for improving public health and safety. For example, 
enhanced methods of drug/adverse event detection in observational clinical data could 
facilitate the prioritization of drug/adverse event relationships for critical review. Given 
the extent of the exposed population and the prevalence of adverse drug events, an 
improvement of even a few percentage points could have a substantial impact.  
                                               
41 Overall results were slightly higher (~ 0.08) when calculated using only pairs where drug occurrence ≥ 100 or 500. 





In Chapter 4, LBD methods were used for feature selection of confounders to 
adjust for plausible confounding with the same set of clinical data. Both single predicate 
(CAUSES and PREDISPOSES) and dual predicate (“drug TREATS x; x 
COEXISTS_WITH adverse_event”) discovery patterns were deployed to identify 
confounding variable candidates. With the single predicate discovery patterns, the 
influence from the confounder was only exerted explicitly in the literature on the 
outcome and can be thought of as an alternative etiology. Dual predicate discovery 
patterns performed the best overall with a modest ~ 0.02 AUROC improvement over 
unadjusted models. My analysis was that the dual predicate discovery patterns identify 
confounding variable candidates that influence both predictor and outcome, fulfilling the 
graphical criteria (Judea Pearl, 2009). In the Chapter 4, I used a different dual predicate 
discovery pattern, and these results affirm previous observations about the utility of dual 
predicate discovery patterns for identifying confounders with the bonus that causal 
models with validated “true” confounders improved upon the performance of adjusted 
dual predicate statistical models. I reduced the False Discovery Rate (FDR), where 
𝐅𝐃𝐑 = 	𝐓𝐫𝐮𝐞	𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐓𝐫𝐮𝐞	𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞+ 𝐅𝐚𝐥𝐬𝐞	𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 , from 0.5 to 0.38 with causal 
models. Although the performance increase is substantive and better in general adjusted 
standard statistical models (for purely EHR-based pharmacovigilance), it does not 
approach the performance obtained in the work of Li et al. with extra-EHR data sources, 
where adjusted EHR statistics with adjusted FAERS performance improved upon 





AUROCs improved across all adverse events with this chapter’s method in 
contrast to the results from Chapter 4. In addition, the improvements were more 
considerable overall – an 0.08 improvement in the aggregate. Starting with similar 
baseline scores, Li was able to increase the AUROC considerably by integrating FAERS 
data (Y. Li, 2015). This indicates that a future direction of research should be in 
synthesizing data-driven confounding variable discovery methods with literature-derived 
covariates to see how this affects performance. Note that the discovery pattern of “drug 
TREATS confounder; confounder CAUSES adverse_event” only identifies 
comorbidities, while the discovery pattern in Chapter 4 identifies both comorbidities and 
co-medications.  
Limitations of (and Lessons from) the Current Approach. One limitation is 
that my search for confounders was relatively shallow, having commenced confounder 
permutations after reaching five validated confounding variable candidates. 
Computational demand scales with the number of confounders. Five validated 
confounding variable candidates result in thirty-one permutations per drug/adverse event 
pair. Increasing to ten confounding variable candidates would leave 1032 permutations - 
which can take twelve hours to run on a Linux workstation with 64GB RAM and eight 
Xeon CPUs. I chose five confounding variable candidates because I could collect results 
for all drug/adverse event pairs for a single adverse event within a reasonable amount of 
time (7-8 hours overnight). There may be some theoretical justification for using a 
limited number of confounders as it is possible to “overcontrol” causal associations 





of confounders to ten had the effect of reducing recall (recovering causal edges in the 
cases/True Positives), while increasing specificity (decreasing the number of False 
Positives).  
An additional limitation arises from the available EHR data, which may not have 
a sufficient number of drug/adverse event co-occurrences, as the performance from 
analyses of FAERS data is usually better than results from any EHR data source (Y. Li et 
al., 2015a).  
One perplexing problem arose from three drug/adverse event pairs for myocardial 
infarction for which the proposed method could not identify any confounders (these are 
not included in Table 5). I suspect that confounders for myocardial infarction identified 
by my method, e.g., hypertension, coronary arteriosclerosis, metabolic syndrome, could 
have helped if incorporated into these models. Note that the discovery pattern limits 
result sets of potential confounders to comorbidities, although co-medications (for 
example, aspirin and acetaminophen for gastrointestinal bleeding and liver failure, 
respectively) often make exemplary confounder candidates, so there remains the question 
of the optimal mixture of confounder types. These factors (along with SemRep’s low 
recall of ~ 0.64) may have impacted my system’s performance by missing potential 
confounders (Kilicoglu, Fiszman, Rosemblat, Marimpietri, & Rindflesch, 2010). 
Another consideration is that reference data sets, however essential to the scientific 
enterprise, may not be entirely accurate, as knowledge about drugs and their side-effects 








The implicit assumption in the calculating of the score of each 
drug/adverse event pair is that each permutation of the set of confounders is 
equally valid. This simplifying assumption, while likely invalid, was nonetheless 
useful as overall performance eclipsed that of the statistical models in Chapter 
4. This could be addressed by using an information theoretic metric to 
encapsulate data/model goodness of fit, e.g., Bayesian Information Criterion, 
for each permutation of a confounder set, where each permutation could be 
assigned a weight.  
The next chapter counters with a more principled approach to causal 
modeling, while building on the insights and essential lessons of what worked 
for LBD predictive modeling: respectively, dual predicate discovery patterns to 
identify focal sets of confounding variable candidates (Chapter 4) and the 
exploitation of the directionality inherent in causal predicates (Chapter 5). The 
experiment described in Chapter 6 infers the data generating process gleaned 
from the EHR data, whereby such generative causal models can be used to 






Chapter 6: Quantifying the Average Treatment Effect from a Mutilated DAG  
… [T]o explain an historical event is to find the reasons for its occurrence, and to 
do that is to re-enact the circumstances and states of mind of the actual agents 
whose actions brought about the event in question. The historian gives ‘the’ 
reasons for that event when he gives ‘their’ reasons for it.  
  Dov Gabbay, 2006, pg. 94 
 
In the experiments described by the previous two chapters, the struggle was to 
first identify what species of intervening variable would be most helpful for the 
task of amplifying pharmacovigilance signals in EHR data. Dual predicate 
discovery patterns were found to be the most effective. These reasoning 
pathways proved effective for identifying not only concepts that were associated 
with both the predictor and outcome variables, but mutual causes of them both, 
i.e., the operative definition of confounder. This chapter presents an experiment 
to explore the frontiers of what such precisely defined confounders can do42. 
 
A causal model by definition describes a data generating process43. In this 
study, data generating processes are functional causal DAGs. As in the previous 
chapter, expert knowledge derived from the literature is directly mapped as a 
graph prior and instantiated with observational data derived from EHR. The 
novel feature of the current experiment is that the causal DAG generate 
simulated data from a mutilated posterior model with which to calculate 
average treatment effects, or ATE.  
                                               
42 Owing to their ability to answer counterfactual queries, Koller distinguishes the class of causal models 
discussed in this chapter as being “functional causal models” in contrast to plain causal models (Koller et 
al., 2009). In this chapter, techniques are described which can not merely describe conditional probability 
distributions with causal assumptions, but answer counterfactual queries. 






The methods evaluated in this chapter are the state-of-the-art refinement of my 
methodology and constitute a principled method for the incorporation of 
literature-derived confounding variable candidates into causal models. 
 
6.1 Introduction 
This study addresses the weaknesses of the ad-hoc permutation-based procedure 
described and evaluated in the previous chapter and documents the current stage of 
evolution of the methods developed for this dissertation. Specifically, this study assesses 
the ability of LBD-informed causal inference models to quantify the effect of the 
explanatory variable (drug exposure) on an outcome of interest (an adverse event) using 
observational clinical data derived from EHR. The identification of literature-derived 
confounders can facilitate the process of de-confounding, (or "screening off" spurious 
correlations from descriptive statistics) in observational data, by imposing constraints 
from a priori domain knowledge on the topology of the causal graph. By incorporating 
confounders into causal models, one can perform experiments/interventions with the 
resulting data generating model (J. Pearl et al., 2016; Judea Pearl, 2009; T. J. 
VanderWeele & Shpitser, 2013).  
6.2 Technical Background 
The following subsections provide an overview of the essential mathematical machinery 
and concepts required estimating ATE. These core components can be summarized as 
follows:  





2.) Counterfactual queries via graph mutilation (section 6.2.2).  
3.) Mutilated graph simulations for ATE(𝐝𝐫𝐮𝐠	Þ	𝐚𝐝𝐯𝐞𝐫𝐬𝐞_𝐞𝐯𝐞𝐧𝐭) (section 
6.2.3). 
Since the graphical approach for representing causal relationships (wherein nodes 
represent variables and directed edges represent causal relationships [or “dependencies” 
between variables]) is the most intuitive to grasp, the next section starts with graphs 44.  
6.2.1 Graph factorizations and conditional independence 
A Bayesian network consists of a network structure as directed edges that encode intra-
node (variable) dependencies and a the conditional distribution of each nodes’ 
adjacencies. When observed values of variables represented are populated, the network is 
said to be instantiated. If the joint density distribution inferred from these values are 
reflected in the anticipated network structure, that structure is said to be compatible with 
its instantiation (Darwiche, 2009; Koller et al., 2009).  
Consider a data set A that consists of a set of random variables X and is described 
by a directed acyclic graph G. The (causal) Bayesian network B = (G, X) and Q denote 
the parameters of the global distribution of X, such that Q is i.i.d. with X, so that B = (G, 
Q) (and Q can denote the sufficient statistics of appropriate marginal and joint 
distributions given A, e.g., Bernoulli/binomial/multinomial. if discrete, Gaussian/Poisson. 
if continuous, and so on) (Darwiche, 2009). The structure and parameter learning process 
                                               
44 Beyond being merely easy for humans to interpret, graphs have convenient mathematical properties that 
are useful for summarizing dependency relationships a set of random variables. In short, dependency 
relationships may be easily translated into either graphical or factorization form. These properties are 





(noted above) is decomposable into the following factors (Koller et al., 2009; J. Pearl, 
2014; M. Scutari & Denis, 2014; Marco Scutari, 2009) [Equation 1]:  
𝑷	𝑩 𝑨  = 𝑷	𝑮,Q 𝑨  = 𝑷	𝑮 𝑨 	𝑷	Q 𝑮,𝑨 . 
P(G|A), the first factor on the right side of Equation 1, denotes the structure (topology) 
of the graph and can be further decomposed as follows [Equation 2]:  
𝑷	𝑮 𝑨  = 𝑷	𝑮 	𝒂𝒓𝒈𝒎𝒂𝒙	∫ 𝑷	𝑨 𝑮,Q 	𝑷	Q 𝑮 	𝒅Q	 	45 
P(G) represents the “subgraph”46 of the Bayesian network derived from domain (expert) 
knowledge as a structural (graph) prior. G encodes conditional probabilities of the 
random variables in X from data A parameterized by Q.  
 
Figure 7. Illustration of a “true confounder” with a set of random variables {x, y, z}.  
 
 
                                               
45 Translated into plain English, this expression says: “find the values of parameter Q that maximize the 
area under the curve (are the most likely) for graph G dataset A.” 
46 The graph “subgraph” refers to how there may be unanticipated dependencies given the actual input data 
that were not recalled in the literature. In LBD research, this refers to the subset of dependencies identified 





6.2.2 Counterfactual queries via graph mutilation.  
Given a set of random variables {x, y, z}, where z is a confounder that influences both x 
and y, assume that we do not know the relationship between x and y. From a priori 
knowledge (or experience47) we know that the value of z determines x and y. Variable z 
is said to be their common “parent,” while x and y are z’s “children.” Since x and y have 
a parent in common (“a mutual cause”), their values are statistically correlated. A 
directed (“causal”) edge is drawn from x to y to represent the relationship about which 
we wish to know more. The task is to determine the likelihood of x to influence or 
determine the value of y, even in the presence of mutual cause z that influences them 
both as depicted in Figure 8 below. Graph G is depicted below and the relationships 
between its variables encodes their dependencies (G’ will be explained later).  
                                               






Figure 8. Illustration of graph mutilation/manipulation. To make the connection clear, in 
calculating the Average Treatment Effect, one is “severing” the relationship between z 
and x, cutting off the “back-door path”.  
 
G factorizes as the following joint probability distribution [Equation 3]: 
𝑷	𝒙, 𝒚, 𝒛  = 𝑷	𝒛 	𝑷	𝒙 𝒛 	𝑷	𝒚 𝒙, 𝒛  
Since the task is to eliminate the noise emitted by the effect of z on x [Equation 4]: 
	𝑷(𝒙, 𝒚, 𝒛) 𝑷(𝒙|𝒛)  = 𝑷	𝒛 	𝑷	𝒚 𝒙, 𝒛  
Note that the factorization of graph G’ is represented in the factorization on the right-
hand side of Equation 4. Given the dependencies depicted in the graph and its respective 
factorization properties, a question one might ask is: how might we estimate the 





such that it is no longer susceptible to influence from z. This “fixing” or “setting 
constant” the values of the explanatory variable x is the essence of the “do(.)” operator 
introduced below.  
To determine the direct effect of x on y, one can mutilate48 the graph by setting 
(randomizing) the values of x (to 1 and then to 0), such that the post-intervention 
distribution to reflect G’ above can be denoted by the following truncated factorization49 
(P(x|z) is dropped as x becomes parentless [independent of z] due to randomization) 
[Equation 5]: 
𝑷	𝒛, 𝒚 𝒅𝒐	𝒙   = 	𝑷 𝒎𝒖𝒕𝒊𝒍𝒂𝒕𝒆𝒅 (𝒛)	𝑷 𝒎𝒖𝒕𝒊𝒍𝒂𝒕𝒆𝒅	𝒚 𝒙, 𝒛   = 𝑷	𝒛 𝑷(𝒚|𝒙, 𝒛) 
By dividing Equation 3 by P(x|z) as per Equation 4 and combining it with Equation 5, I 
obtain a telling pre- and post-intervention ratio [Equation 6]: 
𝑷	𝒛, 𝒚 𝒅𝒐	𝒙   = 		𝑷(𝒙, 𝒚, 𝒛) 𝑷(𝒙|𝒛)  
We can perform adjustment by marginalizing over z (J. Pearl et al., 2016) [Equation 7]: 
𝑷	𝒛, 𝒚 𝒅𝒐	𝒙   = 		𝒛  𝑷	𝒛 𝑷(𝒚|𝒙, 𝒛)  
Counterfactual and Potential Outcomes Framework. Confirming our intuition, 
the P(x|z) is critical for estimating the effect of do(x). To nullify the dependency between 
the confounder and the explanatory variable, the explanatory variable x can be set to a 
value of 1 and then to 0, where 1 indicates presence (or treatment/case) and 0 denotes 
absence (or placebo/control) (K. Lee, Small, & Rosenbaum, 2018; J. Pearl et al., 2016; 
Rosenbaum & Rubin, Donald, 1983; M. Scutari & Denis, 2014) [Equation 8]:  
                                               
48 Elsewhere, this is referred to as “graph surgery” (S. Greenland et al., 1999; Judea Pearl, 2009). 





𝑷	𝒚 𝒅𝒐	𝒙   = 𝑬	𝒚 𝒙 = 𝟏 − 𝑬(𝒚|𝒙 = 𝟎) 
Equation 8 is a means to express the severed dependency of P(x|z) in G’. When 
the graph is modified to remove the influence of z on x, a more accurate picture of the 
relationship between x and y emerges. This intuition that underlies the notion of the 
“back-door” criterion is that the graph is to permit the estimation of the causal influence 
of x on y irrespective of the influence of z on x (the “back-door path”). The apparent 
effect of x on y may or may not be spurious, and this procedure facilitates this estimation. 
The “back-door criterion” is discussed at length elsewhere (Morgan & Winship, 2015; 
Judea Pearl, 2009; T. J. VanderWeele & Shpitser, 2013).  
Note the operations just described are “counterfactual” in that we are not using 
the joint distribution from the data, but estimating the relationships from a manipulated 
distribution. Recall that the relationship between z and x (nullifying the “back-door”) is 
severed and the values of x are fixed to 1 and 0, so as to measure an average effect of y 
on x. P(y | do(x)), referred to as “average causal estimate” or “average treatment 
estimate”, or ATE, is not the same as P(y|x) (association). However, they could be the 
same, in an hypothetical case, if the x and y are not confounded50.  
6.2.3 Mutilated graph simulations for ATE(𝒅𝒓𝒖𝒈	Þ	𝒂𝒅𝒗𝒆𝒓𝒔𝒆_𝒆𝒗𝒆𝒏𝒕) 
                                               
50 Note also that we cannot determine how an individual patient “p” would fare given a treatment since at 
one time slice patient p’s outcome Y can only hold discrete values, 1 or 0, not both. This is why the 
expectation or mean is calculated (the average treatment effect). In performing the ATE calculation, there is 
an explicit assumption that the patient has two values simultaneously. This is why the potential outcomes 





In probabilistic graphical models, the most common way to estimate the set of 
parameters Q	is to perform a maximum likelihood estimate. This finds the best set of 
edges given input data (and assumptions from domain knowledge about the orientation of 
the edges).  
However, for causal models, one does not stop at an estimate from the joint 
density distribution but uses that distribution as the means to generate data from a 
perturbed or “mutilated” distribution. In this mutilated distribution, the predictor 
variable’s values are fixed as per Equation 8 above (to remove dependency to a common 
cause [the P(x|z) term in the graph factorization]).  
A causal model specifies both qualitative (the edges/arcs between nodes/vertices 
in the graph) and quantitative relationships. The latter is embodied in another stream of 
influence on causal inference deriving from econometrics, more specifically of structural 
equations modeling (SEM) (Bollen, 2014; Bollen & Long, 1993; Goldberger & Duncan, 
1973; J, 2008; Judea Pearl, 2009).  
An example will illustrate a simple (causal) SEM as a data generating process 
(Hendry & Doornik, 2014). Take variables {x, y, z} and presume that their respective 
relationships and parameters Q have been learned from a set of observational data. Let us 
presume that these variables are related to each other as per Figure 7 (from earlier in this 








From these equations, we can see that z is exogenous, while x is dependent on the value 
of z and y is dependent on the values of both x and z. With this data generating model, 
the average effect of x on y may be estimated by shutting off the relationship between x 
and z by setting the value of x value to 1 and subsequently to 0 (severing the “back-door” 
path, i.e., the P(x|z) term in the graph factorization).  
The results of this operation are a new “mutilated” set of equations that now look 




To calculate the average treatment effect, or ATE, one is calculating an expectation or 
mean. This mean is not the mean of the observed, original joint density, but those of the 
mutilated models. Using these mutilated models (data generating processes) to simulate 
data, a conditional probability query can be performed with x = 1 and x = 0 on data 
generated from the new mutilated distributions, then one simply subtracts the results 
[Equation 9], where E is the expectation or mean51: 
                                               
51 𝐸 = k
l





𝑨𝑻𝑬(𝐱	Þ	𝐲) = 𝑬	𝒚	 	𝒅𝒐(𝒙 = 𝟏)) − 𝑬(𝒚	|	𝒅𝒐	𝒙 = 𝟎 ) 
	= 	𝟏 𝒏 	𝒊 = 𝟏 𝒏 	𝒚	 	𝒙 = 𝟏) − 	 	𝟏 𝒏 	𝒊 =
𝟏 𝒏 	𝒚	 	𝒙 = 𝟎)	  
To summarize: to compute the ATE, a mean is calculated from simulated data drawn 
from the joint density distribution of the two mutilated causal Bayesian network (where x 
is set to 1 and subsequently to 0)52. In graphical terms, it severs the backdoor path (flow 
of information from the confounder to the predictor. To define ATE in coarse terms, the 
ATE is the mean “delta” (change) that one could expect of an adverse event occurring 
from each increase drug exposure in that population; it is sometimes referred to as the 
stable unit treatment value assumption53, or SUTVA (Cox, 1958). 
In machine learning, sequential (data generating) processes such as those described above 
may be simulated using what is variously referred to as “particle filtering” or “logic 
sampling” methods (Darroch, Lauritzen, & Speed, 1980; Fung & Chang, 1990; M. 
Henrion, 1987; Max Henrion, 1988; Koller et al., 2009; M. Scutari & Denis, 2014). In 
logic sampling, one has a set of variables that are defined as parameterized distribution 
functions. To simulate data, the process runs forward. Depending on the implementation, 
there is a “burn-in” period of iterations to allow for the sampling to attain the intra-
variable parametric targets (Darwiche, 2009; Koller et al., 2009; M. Scutari & Denis, 
                                               
 
52 The broad strokes of this method were first devised by Polish agronomist Jerzy Neyman who desired to 
answer “what if?” or “counterfactual” questions about which seeds to plant given what is known about their 
crop yields (Neyman, 1937; Rubin, 1990). 





2014). For mutilated graphs an updated rendition of logic sampling is used called 
“likelihood weighting” (M. Scutari & Denis, 2014; Shwe & Cooper, 2013). 
Recap: synthesizing the pieces. The steps for simulating data to perform such an 
estimate from EHR data are as follows:  
1. Learn the graph structure with oriented edges between variables for each 
drug/adverse event pair in the OMOP reference dataset (Ryan, Schuemie, et al., 
2013). 
2. Given the data, learn the parameters Q that define the intra-variable relationships. 
3. Generate data using the mutilated versions of the causal models, fixing 
explanatory/drug exposure variable (“evidence”) to 1 and 0, and performing 
conditional probability queries on the simulated data. 
4. Calculate the ATE from the mutilated model. 
5. Aggregate the results to calculate AUROC from rank ordered ATEs for the 
OMOP reference data set. 
Steps 1 and 2 of the procedure are described in section 6.2.1 and Steps 3 and 4 are 
described in sections 6.2.2 and 6.2.3.  
6.2 Materials and Methods 
6.2.1 Data and Knowledge Resources.  
EHR data. To evaluate this hypothesis, the same pre-processed EHR data and 
reference dataset were used as in Chapter 4 and Chapter 5 (Ryan, Schuemie, et al., 2013; 





Discovery Pattern for Confounding Variable Discovery. Semantic Vectors 
provides an interface that permits searching PSI spaces for concepts that populate 
particular predicate discovery patterns, which I used to identify the most strongly 
associated confounding variable candidates for each drug/adverse event pair. I used the 
following discovery pattern to identify possible confounding variable candidates: “drug 
TREATS confounder; confounder CAUSES adverse_event” (the same discovery 
pattern as in Chapter 5). This discovery pattern was chosen for its ability to identify 
mutual causes of both the explanatory and outcome variables in Chapter 5. 
6.2.2 Methods 
What follows in this section is a brief breakdown/overview. This is followed up with 
more details about each step of the procedure.  
Core steps to evaluate ATE. The core steps of the method to quantify ATE are as 
follows: 
1. Query PSI vector space for confounders in ranked order of relevance. 
2. Test each confounding variable candidate for directed edges to both the drug 
and the adverse event using the clinical data, stopping after obtaining ten54 valid 
confounding variable candidates for each drug/adverse event pair. 
                                               
54 I tested many variations of covariate threshold. In most cases, the more covariates identified, the better 





3. Build predictive (statistical [multivariate logistic regression] and causal) 
models for each drug/adverse event pair incorporating the validated LBD-derived 
confounders. 
4. Calculate the ATE using mutilated simulation data generated from the 
causal models for each drug/adverse event pair. 
5. Calculate AUROCs from rank ordered scores (baseline regression coefficient, 
adjusted regression coefficient, ATE) for the drug/adverse event pairs in the 
reference dataset. 
The next subsections will break the novel procedures above into manageable parts. 
 
6.2.2.1 Testing Confounding Variable Candidates.  
There are two critical tasks after identifying confounding variable candidates concepts:  
1.) Determine if confounding variable candidate appears in the data (if not, 
move to the next confounding variable candidate). 
2.) Determine if the confounding variable candidate fulfills the graphical 
criteria as a confounder.  
If the confounding variable candidate is not in the clinical data, it cannot be instantiated. 
However, if there are data for the identified concept, then it is tested. Simply stated, in 
order for a confounding variable candidate to be retained for the purposes of building the 
causal model, i.e., becomes part of the “causal story”/”focal set”, it must first be 
instantiated with EHR data along with the drug and adverse event. If there is there is a 





Ü confounder Þ adverse event, then the confounding variable candidate is retained for 
the next step (building the model).   
To construct the causal models for testing confounding variable candidates, the 
hill climbing algorithm in the bnlearn55 R package (M. Scutari & Denis, 2014; Marco 
Scutari, 2009). The hill climbing algorithm recursively adds and subtracts directed edges 
until the Bayesian Information Criterion is minimized. Note that the purpose in the 
current experiment is not so much to learn structure, but to assume that there is a 
relationship between the putative predictor/cause (drug exposure) and outcome (the 
adverse event). The mutual causes or literature-derived confounders are used to screen 
off the relationship between the drug and the adverse event.  
The output consists of a family of score-equivalent graphs which encode plausible 
dependency relationships given these data such that the orientation of the directed edges 
could not be determined from the data alone, i.e., graphs encoded by this structure have 
the same BIC score (Heckerman et al., 1995, 1995). However, background knowledge 
can be used to orient these edges, as causal predicates have inherent directionality. The 
resulting graph structure that results from incorporating literature-derived confounding 
variable candidates have a graph within this equivalence class with directed edges to both 
the drug and adverse event (“confounder inclusion criterion”). 
                                               
55 The primary attractiveness of the bnlearn package stems not from its Bayesian structure learning 
prowess, but its capacity to do most of the “functional” causal modeling toolbox sufficiently well and to 
run in batch processes from the command line. For a formal comparison of causal Bayesian structure 





6.2.2.2 Building causal models 
Once the threshold for the number of confounding variable candidates has been reached 
(the number of covariates) for inclusion in the focal set, the next step is to use these 
concepts to populate a causal DAG/model.  The causal DAG is instantiated with the 
variable values in the EHR data. In this step, EHR data and an initial skeleton of a graph 
(using the edge/arc orientations from the literature) is constructed.  
To construct the LBD-informed causal models, the hill climbing algorithm in the 
bnlearn R package (M. Scutari & Denis, 2014; Marco Scutari, 2009) is used, as per the 
previous step, is used to learn the rest of the (inter-confounder) relationships and to fit a 
model using maximum likelihood estimate (MLE). MLE attempts to identify an optimal 
set of parameters given the graph structure and the observed data. These parameters may 
then be used to generate simulated data (as per section 6.2.3).  
The nodes of confounding variable candidates tend to be (but are not always) 
highly correlated, so there is lots of “cross-talk” between the confounders. An example 






 Figure 9. Illustration of a causal graph instantiated with EHR data. Drug = methotrexate, 
adverse event = acute liver failure (“ALI”). From the OMOP reference dataset (Ryan, 
Schuemie, et al., 2013), positive control. For clarity, the number of confounders has been 
reduced.  
The graph provides an intuitive picture of some of the causal interactions between these 
variables. For example, it is clear from the graph that methotrexate is prescribed as a 
treatment for (therefore, observing it is CAUSED BY) psoriasis, ulcerative colitis, and 
rheumatoid arthritis: but not for hypercholesterolemia. Others are more difficult to 
interpret. For example, while one might anticipate raised cholesterol in advanced liver 
disease, hypercholesterolemia is not commonly considered as a possible cause for liver 
failure. Nonetheless, the ability to interrogate a visual representation of the relationships 
inferred by the model can be informative in interpreting the assertions of causality that 





6.2.2.3 Calculate the ATE using mutilated simulation data  
 As mentioned earlier, a causal model not only describes a data generating process 
(that which has been learned from observational or experimental data or both), but a 
model that may be perturbed/mutilated/manipulated to see how the variables behave 
under duress. The next sub-subsections describe how to implement these simulations 
(Judea Pearl, 2009).  
 Simulating the data. Once a graph and its parameters have been learned from the 
data, the next step is to manipulate this model.  
 In a standard conditional probability query (CPQ), the CPQ generates data using 
the parameters of model, i.e., the joint density distribution learned from the observations. 
The values of the variables of interest and an “n” for the number of simulations may be 
applied as per the investigator’s interest.  
 The R package bnlearn provides the means to perform mutilated conditional 
probability queries. In a mutilated CPQ, the investigator sets the “evidence”, e.g., drug = 
{1, 0}, and specify an “event”, e.g., adverse event = 1.  By setting the evidence for drug to 
1 and then to 0, specifying the event to adverse event = 1, and running the query, and 
subtracting the two results (as per Equation 8 and Equation 9), bnlearn‘s mutilated 
CPQ function can calculate an ATE for each drug/adverse event pair from the EHR data 
using weighted logic sampling simulation (Fung & Chang, 1990; Koller et al., 2009; M. 
Scutari & Denis, 2014). For the results below, 	10 9  simulated EHR record instances 





implemented with the weighted logic sampling option in the bnlearn R package (M. 
Scutari & Denis, 2014; Marco Scutari, 2009). 
Evaluation Procedure. Coefficients from logistic regression were used to 
calculate baseline scores. ATE was estimated by performing a conditional probability 
query on mutilated graphs for each drug/adverse event causal model, as per Equation 8. 
To evaluate performance, Area Under the Receiver Operating Characteristic curve 
(AUROC) was calculated based on the ranked order of the ATEs.  
6.3 Results  
Parameter estimates from causal models improved performance over logistic regression 
for three of four adverse events. Causal models improved upon unadjusted statistical 












Table 6  
Results from Average Treatment Effect (ATE) 
Adverse events  Total Unadjusted Adjusted Causal Models 
AKI (Acute Kidney Injury) 22/62 0.5672    0.5242 0.6957 
ALI (Acute Liver Injury) 77/34 0.4798 0.5092 0.594 
AMI (Acute Myocardial 
Infarction) 
35/63 0.556 0.5424 0.5456 
GIB (Gastrointestinal Bleeding)  24/64 0.5417 0.5651 0.5866 
Overall 158/223 0.4782 0.5054 0.5849 
Note. This table presents the AUROCs as calculated from the aggregated correlation 
coefficients from logistic regression (unadjusted and adjusted) and ATEs from the causal 
models. Pairs = number of test/control drug/adverse events from the OMOP reference 
dataset (Ryan, Schuemie, et al., 2013). AUROCs in bold indicate that the causal models 
outperformed the baseline models for that phenotype.  
 
6.4 Discussion 
Causal models. There were improvements with causal models in all four adverse 
events. The overall improvement was consistent and not significantly better than the 
results from the chapter previous. The improvements for GIB and AKI over their 
respective baselines were more modest for the causal models than for some of the 
regression models in Chapter 4. An unexpected and notable improvement came from 
ALI. Such an improvement for ALI has been absent in the results from the experiments in 





The experiment in this chapter focuses on creating what Koller calls functional 
causal models (Koller et al., 2009). In a functional causal model, one does not stop with a 
picture or a joint density distribution, but takes these two (the graph and the distribution) 
as a data generating process for further exploration and as a means to explore 
hypothetical questions and scenarios that may not be present in the original/observed 
data. That is, the experiments in this chapter are not only data-driven, but model-driven. 
The nature of the improvement in this chapter is more conceptual than in the actualized 
improvement of performance. That is, the advance described allows for more complex 
models that will be addressed in the next chapter. 
Logistic regression models. The adjusted logistic regression scores have been 
included to see how useful this discovery pattern is for logistic regression. The 
improvements overall were slight compared with causal models and did not fair well in 
comparison with the dual predicate discovery pattern “drug TREATS x; x 
COEXISTS_WITH adverse_event” applied to the EHR data in Chapter 4. This may be 
because the “drug TREATS confounder; confounder CAUSES adverse_event” 
discovery pattern identifies only comorbidities, while “drug TREATS x; x 
COEXISTS_WITH adverse_event” can also identify co-medication-type confounding 
variable candidates. This indicates that discovery patterns besides “drug TREATS 
confounder; confounder CAUSES adverse_event” should be explored to supplement co-
morbidity-type confounders identified by that discovery pattern in future work in LBD-





Li reported notable improvements using data-driven confounding discovery 
methods (Y. Li, Ryan, Wei, & Friedman, 2015b). Inasmuch as natural language 
processing (NLP) facilitates research in the text mining of EHR, NLP can also be a 
limiting factor. Confounders that are present and have been “measured” in the EHR may 
be absent on the literature side; conversely, not all useful confounders may have been 
identified in the literature. In light of this, logical follow-up would be to integrate data-
driven confounding discovery methods with the current literature-based approach. 
For the sake of comparison, the AUROCs of several EHR-based Pharmacovigilance 
methods has been included below in Table 7. Note that the performance patterns are not 
strictly comparable owing to different sample sizes and populations, but have been 
included here for convenience and to provide context. Note the similar starting points for 
both Li et al. (Y. Li, 2015; Y. Li et al., 2014) and UTH. The causal graphs improve upon 
the performance of the regression-based models, but fare poorly in comparison with 
meta-analysis. However, should the causal models be the starting point, meta-analysis 

















Li et al. 
baseline 
 











Li et al. 
Meta- 
Analysis 
Overall 0.50               0.53 0.51 0.51 0.58 0.58 0.73 
Note. This table presents the AUROCs as calculated from the aggregated correlation 
coefficients from logistic regression (unadjusted and adjusted) and scores from the causal 
models from the OMOP reference dataset (Ryan, Schuemie, et al., 2013).    
 
Models of 391 of the 399 drug/adverse event pairs in the OMOP reference dataset 
(Ryan, Schuemie, et al., 2013) were constructed. In some cases, confounding variable 
candidates were absent (as was the case for three drug/adverse event pairs for MI in the 
previous chapter). Having set the threshold to ten, the models of five drug/adverse event 
pairs were not able to constructed as the number of validated confounders did not reach 
the threshold.  
This chapter has evaluated a method to calculate the Average Treatment Effect56, 
or ATE, using EHR data. Calculating ATE is but one step toward harnessing the richness 
of EHR data for pharmacovigilance. The steps beyond ATE will be discussed in the next 
and final chapter. 
Work on the methods described began with a vague idea that intervening 
variables having mechanistic causal relationships could be critical for 
                                               
56 The fundamental problem of causal inference is that causes cannot be directly observed (but they may 
be inferred from the average value of the response between exposed and unexposed population), as per 





predictive modeling. The research has progressed from an amorphous, 
exploratory conception of “in-between” variables to an increasingly refined 
definition of confounding. The limitations, contributions, and directions of 






Chapter 7: Summary, Contributions, and Limitations 
In this, the concluding chapter of my dissertation, I will summarize my research, 
underscore its scientific contributions and limitations, and provide some ideas on how I 
plan to overcome those limitations in future work.  
Innovations of Present Work. The first noteworthy accomplishment of this work 
is the development of a generalizable method through which knowledge extracted from 
the literature can be used to identify confounding variables for statistical and causal 
modeling. Confounding variable discovery was achieved by adapting methods from 
literature-based discovery (LBD) and specifically the use of “discovery patterns” 
(patterns of predicates that may indicate relationships of a particular type) to this novel 
task domain. A key finding from this novel component of the project is that when the vast 
majority of variables identified in this manner do, in fact, represent “true confounders,” 
or mutual causes of both predictor and outcome variables (Judea Pearl, 2009).  
In Chapter 4, I demonstrated that literature-derived confounders could be included 
in statistical (logistic regression) models to improve signal detection using a publicly 
available reference dataset.  
In Chapter 5, I showed that literature-derived confounders could be incorporated 
into causal models and using the graph structure of the resulting models alone, there was 





In Chapter 6, I presented a method to estimate average treatment effect, or ATE, of a drug 
to cause an adverse event given observational data derived from EHR and causal models 
informed by literature-derived confounders. The ATE was estimated by:  
1.) learning the topology of the observational data given literature-derived 
confounders and accompanying subgraph structures inferred from semantic 
constraints;  
2.) estimating model parameters (the joint distribution function) of the causal 
model that has been learned from the clinical data; and  
3.) performing a conditional probability query on a “mutilated” version of the 
graph by fixing the confounder to drug/explanatory edges to 1 and 0 and 
subtracting these results.  
Calculating the ATE had the effect of modestly improving performance over the purely 
“qualitative” approach to causal inference taken in Chapter 5. However modest the 
improvement, the success of such a principled approach using “functional causal models” 
applied to even cross-sectional data opens many doors for methodological refinement and  
future avenues of research. 
7.1  Contributions  
The contributions of this thesis to the discourse of biomedical informatics, 
pharmacovigilance, and causal inference are as follows:  
1. Novel domain of application of LBD methods. Previous work in LBD 





work has been done in the area of detecting drug/adverse event signals in 
the literature (Bruza & Weeber, 2008; Hristovski et al., 2006; Mower et 
al., 2016; Shang et al., 2014; Smalheiser, 2012). The application of these 
methods in general, and of distributed representations (PSI 
representations) of discovery patterns in particular, to the problem of 
identifying confounding variables for statistical and causal modeling is, to 
the best of my knowledge, entirely without precedent. The present work 
has demonstrated how causal knowledge embedded in the literature can 
map onto observational clinical data to inform causal models. This 
approach has the potential to eliminate a major bottleneck in the statistical 
and causal modeling of observational data – the need for domain experts 
to manually delineate a “causal story” describing variables of interest for 
each hypothesis to be evaluated (J. Pearl et al., 2016). This finding has 
broader implications for the science of informatics, as it shows that 
confounders identified through literature-based discovery are of practical 
utility in improving the accuracy of predictions made from such data. 
2. I show that LBD methods can indeed be used to identify confounding 
variables and that incorporating these automatically identified 
variables improved the accuracy of predictive models (both classical 
statistical and contemporary causal discovery methods). The studies 
that I have presented have shown how if there is sufficient interaction 





suggestive of having the desirable property of being “confounders,” or 
mutual causes of both the predictor and outcome variables, are useful for 
reducing confounding observational clinical data. 
3. The methods proposed may be generalized to other areas of 
biomedicine. For example, these methods may be adapted to identify 
control groups for RCTs (Fokkema et al., 2017). Specifically, a promising 
area in which my approach to identifying confounders may be of value is 
in the area of identifying subgroups for stratification in Phase III clinical 
trials. That is to say that LBD-based identification of confounding 
subgroups/demographic cohorts could be used to augment the scientific 
scope or imagination of human experts and help to address unanticipated 
deficiencies in clinical trials, given for example their being carriers of 
specific alleles or having particular family medical histories. Some cohorts 
of the populate could be more informative or representative for the task of 
assessing safety and efficacy of pharmaceutical profiles before approval 
and release to market. 
4. Regarding a theoretical contribution, this dissertation demonstrates 
how domain knowledge may be used as a means to constrain 
hypothesis space so as to devise an explanation of empirical 
observational data. The automatic generation of hypotheses using 
domain knowledge is tantamount to implementing what is referred to as 





considers the cognitive constraints of the human mind, limits of time and 
memory, it is remarkable what we as a species have been able to 
accomplish. There are some tasks where humans excel, yet it has been 
challenging to develop machines that can perform tractable abduction by 
arriving at a plausible if not an ideal explanation of what has been 
observed (what Herbert Simon refers to as “satisficing”) (SIMON, 1956; 
Herbert A. Simon, 1955). It may be the cognitive limitations of human 
memory forces us to concentrate on a causally relevant subset of features 
(Cheng & Novick, 1990; Danks, 2014; C. N. Glymour, 2001; Holyoak & 
Cheng, 2011). To accomplish such a task requires knowledge of context 
and a database of causal knowledge that describes how the universe is 
organized. In the approach to causal modeling that I have described, the 
models apply semantic constraints given cue terms and process input EHR 
data to infer the causal structure, magnitude of relationship between those 
entities (the interpretation of the “parameter estimate”), and suggestions of 
alternate etiologies or explanations of that input data (H.A. Simon, 2012). 
Specifically, the contribution of this dissertation is to introduce practical 
constraints on the scope of variables upon which causal modeling is 
performed. The modeling of human cognition demands that we place 
constraints similar to those that human reasoners do. While we have a 
strong will to know and to learn, we also operate within constraints that 





human reasoners, constraining causal reasoning in this manner offers 
significant computational advantages and paves a path to large-scale 
automated causal modeling. 
5. The present work demonstrates the utility of causal methods within a 
core area of biomedicine. To the best of my knowledge, except for some 
research in the application of instrumental variables, the present work is 
the first attempt to introduce fully automated causal modeling methods 
within EHR-based pharmacovigilance. 
6. This work demonstrates the utility of functional causal models that 
can answer “what if” queries in biomedicine. Causal models make 
assumptions explicit about a domain of knowledge if the form of directed 
acyclic graphs and the functional forms that define the nodes subsumed in 
them. Functional causal models instantiated with mixtures of 
observational and experimental data allow for scientists to be able to test 
the effects of hypothetical interventions and the falsifiability of their 
causal assumptions in silico.  
 
7.2  Limitations  
One limitation of the present study was that the representation of the input data 
was cross-sectional. In cross-sectional data, the primary unit of analysis is the individual 
EHR record. This coarse-grained, but simple data representation lacks the means to 





incorporates patient-level longitudinal EHR data may address this limitation in future 
work (D, S, & K, 2008; Hoover & Demiralp, 2003; Moneta & Spirtes, 2006). An 
additional limitation arises from the available EHR data which may not have a sufficient 
number of cases (drug/adverse event co-occurrences), resulting in the poor performance 
of the baseline models, apparently a common experience (Y. Li, 2015; Y. Li et al., 
2015b). As adequate performance without confounding adjustment appears to be a 
prerequisite to substantive improvement once confounders were accounted for, this limits 
the scope of application of my methods. This relatively poor performance with EHR data 
alone is not unique to the current work – performance from analyses of FAERS data is 
usually better than results from any EHR data source (Y. Li et al., 2015a). Another 
consideration is that reference data sets, however essential to the scientific enterprise, 
may not be entirely accurate, as knowledge about drugs and their side-effects 
accumulates – recent work has identified specific deficiencies in the reference set that I 
have utilized (Hauben et al., 2016). Current performance is not yet adequate to support a 
practically useful pharmacovigilance system and falls short of the performance obtained 
using other data sources, i.e., meta-analysis. It is not clear that this is only due to 
inadequate numbers of cases and resultant lack of statistical power: there may be other 
limitations of EHR data that come into play here. I believe that this limitation is due to 
the generally poor baseline performance, which:  
1.) constrains the potential of confounding adjustment,  





3.) has been addressed elsewhere successfully by combining EHR and FAERS 
data, which is likely to be a fruitful area for future research.  
7.3  Future Work 
In my future work, I will aim to utilize patient-level longitudinal representations 
of EHR data to address the limitations of cross-sectional causal.  
Another idea to explore would the use of FAERS and EHR data together and the 
exploration of causal modeling using longitudinal patient-level data with structural vector 
autoregression (where patients become their own controls). I will also develop heuristics 
to allow for more in-depth confounder search, and explore the potential application of 
LBD methods to identify instrumental variables.  
In any source of observational data, there is always likely to be confounding. 
Greedy Fast Causal Inference (GFCI), which first runs FGES and then prunes edges with 
a constraint-based structure learning algorithm, is an algorithm which can identify hidden 
latent confounding (Ogarrio et al., 2016; J. D. Ramsey & Malinsky, 2016; TETRAD, 
2017). GFCI, in other words, could direct the LBD mechanism in automated causal 
inference to conduct a recursive search for confounding variable candidates until no 
further latent confounding is discovered (or up to a pre-determined threshold or search 
depth).  
One challenge of integrating heterogeneous data is that it is likely that there is 
missing data. However, these missing data could be imputed and become useful if the 





Finally, I have implemented a method to calculate the Average Treatment Effect, 
or ATE, using EHR data. Calculating ATE is but one step toward harnessing the richness 
of EHR data for pharmacovigilance. Two promising directions for building on the 
methods described (culminating) in Chapter 6 include: calculating controlled direct 
effects (M.A. Hernan & Robins, 2017; Petersen, Sinisi, & Laan, 2006; Robins & 
Greenland, 1992; Tchetgen Tchetgen & Vanderweele, 2014; T. VanderWeele, 2015; T. J. 
VanderWeele, 2012; Vanderweele et al., 2014) and/or implementing Cheng Models 
(wherein the average causal effect of known and established causes are included to 
normalize estimated treatment effects) (Cheng, 1997; Cheng & Novick, 1990; C. N. 
Glymour, 2001; Holyoak & Cheng, 2011).  
7.4 Conclusion  
Better detection methods in pharmacovigilance, if implemented appropriately, 
should result in better public health and less of an onerous burden stemming from adverse 
drug events. Enhanced methods for drug/adverse event detection using more granular 
data would also permit regulatory agencies to prioritize potentially causal drug/adverse 
event relationships for critical review more precisely owing to their severity and 
prevalence. Given the extent of the exposed population, an improvement of even a few 
percentage points could potentially save the lives of many thousands of our loved ones 
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Appendix: Causal Graph Examples 
Stochastically selected graphs of causal models instantiated with EHR data. 
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